

521,410  
10/521410

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



Rec'd PCT/PTO 18 JAN 2005



(43) International Publication Date  
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number  
WO 2004/008147 A2

(51) International Patent Classification<sup>7</sup>: G01N 33/574

(21) International Application Number:  
PCT/EP2003/007786

(22) International Filing Date: 17 July 2003 (17.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02015944.8 17 July 2002 (17.07.2002) EP

(71) Applicant (for all designated States except US): MAX-  
PLANCK-GESELLSCHAFT ZUR FÖRDERUNG  
DER WISSENSCHAFTEN E.V. [DE/DE]; Hofgartenstr.  
8, 80539 Munich (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ULLRICH, Axel  
[DE/DE]; Brunnstr. 5, 80331 Munich (DE). KNYAZEVA,  
Pjotr [RU/DE]; Hubertusstr. 66, 82131 Gauting (DE).  
KNYAZEVA, Tatjana [RU/DE]; Hubertusstr. 66, 82131  
Gauting (DE). CHEBURKIN, Yuri [RU/DE]; Agnesstr.  
10, 80798 Munich (DE).

(74) Agents: WEICKMANN, Franz, Albert et al.; Weick-  
mann & Weickmann, Postfach 860 820, 81635 München  
(DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSIS AND PREVENTION OF CANCER CELL INVASION

(57) Abstract: The present invention relates to diagnostic and therapeutic methods in the field of malignant disorders. More partic-  
ularly, the invention provides methods of determining the invasivity of malignant disorders and methods for reducing the invasivity  
of malignant disorders including the prevention or treatment of cancer cell invasion.

BEST AVAILABLE COPY

WO 2004/008147 A2

## Diagnosis and prevention of cancer cell invasion

### Description

5

The present invention relates to diagnostic and therapeutic methods in the field of malignant disorders. More particularly, the invention provides methods of determining the invasivity of malignant disorders and methods for reducing the invasivity of malignant disorders including the prevention or treatment of cancer cell invasion.

10

In recent years it has been shown that overexpression of receptor tyrosine kinases (RTK) is in many cases associated with the development of malignant disorders, particularly cancer in mammals including human beings. For example, overexpression of the receptor tyrosine kinase AXL/UFO (ref. 1, 2; Genbank accession No. M 76125) has been implicated in the development of human hematological malignancies. Further, very recent data indicate that signalling of AXL and its ligand GAS6 is involved in angiogenesis, adhesion and survival of cancer cells (ref. 3, 4, 5, 6, 7, 8). In Breast Cancer Research and Treatment (Oct. 1997), Vol. 46, No. 1, pp. 91, Attar, E.C. et al. disclose studies on AXL receptor tyrosine kinase expression in human breast cancer (ref. 33). Dodge Zantek N. et al. have presented MCF-10A-NeoST as a new cell system for studying Cell-ECM and Cell-Cell interactions in breast cancer (ref. 34). They suggest a potential role of AXL in the invasiveness and as a progressing factor for breast cancer. There are, however, no data presented which would demonstrate that overexpression of AXL is correlated with the invasivity and/or metastasis formation in other malignant disorders.

15

20

25

30

One purpose of the present study was to establish expression profiles of genes particularly selected from protein kinases, phosphatases and other signalling genes in malignant disorders, particularly breast cancer and brain

- 2 -

cancer in order to identify novel markers for invasivity and/or aggressiveness. A cDNA hybridization array was used to analyze gene expression profiles of seven highly invasive, fourteen weakly invasive breast cancer cell lines and three normal breast epithelial cell lines. Differences in gene expression between weakly and highly invasive breast cancer cell lines were identified, which enable the definition of a gene cluster correlating with the invasivity of a breast cancer cell line. By using this cluster or combinations of genes therefrom, a discrimination of highly invasive breast cancer cell lines from weakly invasive breast cancer cell lines and normal breast epithelial cell lines is possible.

Further, in an attempt to identify novel receptor tyrosine kinases (RTK) involved in the biology of malignant glioma, the RTK expression profile in human glioma cell lines has been determined by a cDNA microarray technique. Besides EGFR and PDGFR- $\alpha$ , the receptor UFO/AXL was one of the most prominently expressed RTKs. In 7/9 human glioma cell lines tested, UFO/AXL mRNA had a higher expression level than the mRNA for EGFR (Table 4). Inhibition of UFO/AXL signal transduction by overexpressing a truncated, dominant-negative mutant form of UFO/AXL suppressed tumor progression and prolonged survival in mice when compared to cells overexpressing the UFO/AXL wild-type form. In order to study the mechanism of UFO/AXL signalling and its role in glioma growth, tumor cell morphology and tumor cell behavior with respect to proliferation, aggregability, migration, and invasion were assessed *in vitro*. Furthermore, tumor cell behavior, tumor angiogenesis, and tumor perfusion were analysed *in vivo* by intravital multi-fluorescence microscopy. The study indicates a novel role for UFO/AXL, i.e. in mediating glioma cell-cell interactions, glioma cell migration and glioma invasion. UFO/AXL is the first RTK to be implemented in mediating the diffuse-infiltrative, local metastatic growth of malignant brain tumors.

- 3 -

Thus, a first aspect of the present invention relates to a method of determining the invasivity of malignant disorders comprising determining the expression of at least one gene selected from the group consisting of AXL (Genbank M 76125), GAS 6 (Genbank L 13720), MMP14 (Genbank NM 004995), ADAM12 (Genbank AF 023476), ADAM17 (Genbank U 69611), MT3MMP (Genbank NM 005961), FGF2 (Genbank NM 002006), FGF5 (Genbank NM 004464), FYN (Genbank M 14333), LYN (Genbank M 16038), DDR2 (Genbank X 74764), TIMP1 (Genbank NM 003254), HB-EGF (Genbank NM 001945), SGK (Genbank Y 10032), RPS6RB1 (Genbank M 60724), MAP4K4 (Genbank XM 038748), SIRP $\alpha$  (Genbank Y 10375) and Annexin A2 (Genbank D 00017). Further, the expression of the genes Stat 5b (Acc. NM\_012448) or EDG2 (Acc. NM\_057159) may be determined as indicator for the invasivity of malignant disorders, optionally in addition to determining the expression of one or more of the above genes. It was found that a high expression of at least one of the above genes correlates with a high invasivity.

Further, within the present studies a high invasivity was found to correlate with a high expression of at least two of the above genes, in particular AXL and one or more further genes. The one or more further genes can be selected from the genes listed above or from a gene which is already known as a marker for invasiveness.

Thus, the method preferably comprises determining the expression of several of the above genes, e.g. determining the expression of at least two, three, four, five, six, seven or eight genes. More preferably, the method comprises determining the expression of at least the AXL/UFO gene (Genbank M 76125). Further, the method may comprise determining the expression of at least one further gene which is already known as a marker of invasiveness, such as CD44 (Genbank X 66733), vimentin (Genbank X 56134), CAV1 (Genbank Z 18951), CAV2 (Genbank AF 03572), MMP 1 (Genbank M 13509), MMP 2 (Genbank NM 004530),



- 4 -

MMP9 (Genbank NM 004994), M-CSF (Genbank M 37435) and EPHA2 (Genbank M 59371).

5 A correlation between expression of the above gene cluster and particularly the AXL gene and invasivity was found in several types of malignant disorders, e.g. breast cancer, particularly primary breast cancer, prostate cancer, kidney cancer and glioblastomas or other cancers of epithelial origin. Of particular interest is the finding that a correlation exists between expression of one or more of the above marker genes and in particular of  
10 the AXL gene and invasivity of glioblastomas.

Further, it was found that stable overexpression of a dominant negative mutant of the AXL gene is capable of strongly suppressing cell invasiveness and migration indicating that inhibition of AXL function may  
15 block and loss of metastasis formation in highly invasive malignant disorders, such as breast cancer or brain cancer, e.g. glioblastoma. Furthermore, a polyclonal antibody directed against the extracellular portion of AXL has a very strong inhibitory activity on the migration and invasivity of cancer cells, e.g. breast or prostate cancer cell lines. Moreover,  
20 overexpression of wildtype AXL in weakly invasive breast cancer, prostate cancer cell lines and glioma cells significantly increased their invasivity.

These data show that the AXL gene and protein is a promising new target for the prevention or treatment of malignant disorders, particularly for  
25 inhibiting the tumor invasivity and/or metastasis formation in malignant disorders.

Thus, a further aspect of the present invention relates to a method of reducing the invasivity of malignant disorders comprising inhibiting the AXL  
30 gene, AXL ligand gene or protein, or ligand thereof. The method may comprise (i) inhibiting the receptor tyrosine kinase activity of the AXL protein, (ii) inhibiting the expression of the AXL gene, (iii) inhibiting the

- 5 -

interaction between the AXL protein and its ligands, particularly GAS6 and/or (iv) inhibiting the interaction of AXL with downstream signal transducing factors.

5 With respect to AXL protein ligands, laminin G-like domains of GAS6 (GAS6-LG) in particular have been found to be involved in the interaction with the AXL protein, such as AXL binding and activation (Reference 36). In particular, residues of the GAS-LG2 domain, for example Leu<sup>620</sup>, Tyr<sup>660</sup> and Phe<sup>487</sup>, affect AXL binding and/or activation. According to a specific  
10 embodiment of the invention, the method of reducing invasivity of malignant disorders comprises the inhibition of one or more residues of the GAS6-LG, in particular Leu<sup>620</sup>, Tyr<sup>660</sup> and/or Phe<sup>487</sup>.

The present invention relates to the diagnosis or the prevention and/or  
15 treatment of malignant disorders, particularly the tumor invasivity and/or metastasis formation in malignant disorders. Preferred examples of malignant disorders are cancers of the breast, prostate, kidney, colon, lung and glioblastomas. More preferably, the malignant disorder is breast cancer or glioblastomas.

20 In the diagnostic embodiment of the present invention the expression of invasivity-associated genes is determined qualitatively and/or quantitatively. The expression is determined in a sample comprising malignant cells, e.g. from a human tumour patient. The sample may be  
25 derived from tissue sections, biopsy samples etc. or from body fluids. Gene expression in the sample to be tested may be compared with gene expression in control samples, e.g. negative control samples from "normal" cells or weakly invasive malignant cells, and/or from positive controls, e.g. from highly invasive malignant cells.

30 Gene expression may be determined according to methods known in the art, e.g. on the mRNA or transcript level and/or on the protein level.

- 6 -

Measurement of gene expression on the mRNA level may comprise reverse transcription and/or amplification reactions such as PCR. Preferably, gene expression is measured on a nucleic acid array, wherein nucleic acids from the sample to be tested, e.g. RNA or cDNA, is hybridized to an array of immobilized probes specific for the nucleic acids to be tested. A preferred example of a suitable nucleic acid array is described in PCT/EP 02/01073. Alternatively, gene expression may be determined by other methods, e.g. Northern blot hybridization.

Gene expression on the protein level may be determined by immunological methods using antibodies directed against the proteins encoded by invasivity-associated genes. The antibodies may be labeled directly or indirectly by known labeling groups such as radioactive, fluorescence, chemiluminescence or enzymatic groups such as known in the art.

The therapeutic embodiment of the present invention particularly relates to a method comprising the administration of an inhibitor of the AXL gene, AXL ligand gene, AXL protein or ligand thereof in an amount which is effective of reducing the invasivity of malignant disorders to a subject in need thereof. The subject is preferably a mammal, more preferably a human being. The ligand of the AXL protein is preferably GAS6, in particular residues of GASG-LG, as defined above.

The inhibitor of the AXL gene, AXL ligand gene, AXL protein or ligand thereof, e.g. GAS6, may be an antibody, a biologically active nucleic acid or a low molecular weight compound, e.g. a peptide or a non-peptidic organic compound.

In a preferred embodiment the inhibitor is an antibody directed against the AXL protein or a ligand thereof, e.g. GAS6. The term "antibody" relates to polyclonal antibodies and monoclonal antibodies, particularly to chimeric or humanized monoclonal antibodies or to human antibodies. Further, the

term comprises antibody fragments, e.g. proteolytic fragments such as Fab, Fab' or F(ab)<sub>2</sub> fragments or recombinant fragments such as single chain antibody fragments, e.g. scFv fragments. Methods of manufacturing antibodies or antibody fragments as described above are known in the art.

5

In a further preferred embodiment the inhibitor is a biologically active nucleic acid, e.g. a DNA, an RNA or a synthetic nucleic acid analog. Preferred examples of biologically active nucleic acids are antisense nucleic acids, ribozymes or RNA interference molecules directed against the AXL  
10 gene or an AXL ligand gene or a transcript thereof. A further preferred example of a biologically active nucleic acid is a dominant-negative mutant of the AXL gene. Biologically active nucleic acids may be delivered by known procedures, e.g. by using viral or non-viral gene transfer vectors.

15

In a still further preferred embodiment the inhibitor is a peptidic compound, e.g. a peptide having a length of from 4 to 25 amino acids, a cyclic peptide, a peptide derivative or a peptide mimetic derived from such a peptide. Alternatively the low-molecular weight inhibitor may be a non-peptidic organic compound, e.g. an inhibitor of AXL kinase activity. Low-  
20 molecular weight inhibitors may be obtained by screening suitable compound libraries in a method as described in more detail below.

25

Still a further aspect of the present invention relates to a pharmaceutical composition comprising as an active agent an inhibitor of the AXL gene, AXL ligand gene, AXL protein or ligand thereof (e.g. GAS6, in particular  
25 residues from GAS6-LG, as defined above) together with pharmacologically active diluents, carriers and/or adjuvants. This composition is particularly suitable for reducing the invasivity of malignant disorders and/or reducing the metastasis formation in malignant disorders. Depending on the type of  
30 inhibitor used as an active agent, the pharmaceutical composition may be a liquid, a solid, e.g. a powder, tablet etc., an emulsion or a suspension. The composition may be administered by injection, orally, topically,

- 8 -

rectally, intranasally or by any other suitable means. The effective amount of the active agent in the composition may be determined by the skilled person without any undue burden depending on the type of compound and the disease to be treated.

5

The composition may comprise at least one further active agent. This at least one further active agent may be formulated together with the AXL inhibitor in a single composition or in a separate composition which is coadministered with the AXL inhibitor composition. The further active agent may be a cytotoxic or cytostatic agent such as doxorubicin, cis-  
10 platin, carboplatin, an anti-tumor antibody or any combination thereof.

Still a further aspect of the invention relates to a method of identifying and/or characterizing an inhibitor of the invasivity of malignant disorders comprising determining, if at least a test compound is capable of inhibiting  
15 the AXL gene, AXL ligand gene, AXL protein or ligand thereof (e.g. GAS6 as defined above) or protein. More particularly, the method comprises determining, if a test compound is capable of binding to the AXL protein and/or reducing the AXL gene expression. The test compound may be  
20 derived from compound libraries, e.g. peptide or non-peptidic libraries which are subjected to a screening for AXL inhibitory activity. The screening method may comprise the use of a cell-based assay system, e.g. a system using a cell capable of overexpressing the AXL gene. Additionally or alternatively, the method may comprise the use of a cell-free assay  
25 system, wherein the test compound is contacted with substantially purified AXL protein or a fragment thereof in order to determine binding of the test compound to the protein or fragment thereof.

Further, the invention shall be explained in more detail by the following  
30 figures and examples.

**Figure 1. Morphology of normal and breast carcinoma (BC) cell lines when cultured on matrigel-matrix (3D outgrowth).**

Cells were cultured on top of a Matrigel layer for 7–14 days. A, photographs representing the three basic morphologies are shown for the indicated BC cell lines. Magnification was x100 for MDA-MB-231, MDA-MB-435S, BT549 and MCF10A. Determination of the morphology of cells grown on Matrigel was carried out as described previously (10, 11, 12). Briefly, cells (5000 cells/well of a 96-well plate) resuspended in 50  $\mu$ l of culture medium were plated on top of a preset Matrigel coating consisting of 70  $\mu$ l of Matrigel (Becton Dickinson) diluted to 6 mg/ml in -RPMA basal medium salts. After polymerization on the top those 50  $\mu$ l of Matrigel (1.0 mg/ml) was added. Colony outgrowth was monitored over the course of the experiment and photographed at 7–14 days using a Zeiss Axiovert 35 microscope equipped with OpenLab (UK) digital camera. The name of the respective cell line is indicated.

**Figure 2. Classification of breast cancer cell lines by gene expression profile of known kinases and phosphatases. Common gene expression changes (Cluster AXL) in weakly invasive versus highly invasive BC cell lines.**

Gene expression was measured by cDNA array hybridization of RNA (duplicate preparations) from each of the indicated cell lines, as described in "Materials and Methods." The 22 selected genes were differentially expressed in at least 75% of the weakly invasive BC cell lines, the highly invasive BC cell lines (red and green bar, subsequently), or both with median fold-changes of greater than 2-fold. The level of gene expression relative to MCF10A is shown by the colour and shade designated in the key at the bottom of the cluster. Each colour shade encompasses all of the values in the range spanned by the numbers beneath the scale. GenBank accession numbers (see Table 3) and descriptions for each gene, as well as the spot location on self-made arrays membranes are also provided (see separate Table 2 and 3 of genes). Confirmation studies were performed by

- 10 -

Northern (AXL and GAS6) or RT-PCR analysis (Roche system for HER2 expression and amplification, not shown) using the same RNA preparations as in the array. Unless otherwise noted, agreement between the arrays and other methods was within 2-fold, correlative for the majority of samples; qualitative agreement with array underestimating fold-change by other methodology by at least 10-fold. The position of invasive and weakly invasive cell lines were indicated by colour bars, subsequently.

**Figure 3A, B. Classification of primary breast cancer and their cell lines by gene expression profile of the known kinases and phosphatases.**

Gene expression was measured by cDNA array hybridization of RNA (duplicate preparations) from each of the indicated cell lines and primary tumors, as described in "Materials and Methods." The 26 selected genes were differentially expressed in at least 75% of the weakly invasive BC cell lines, the highly invasive BC cell lines (red and green bar, subsequently), or both with median fold-changes of greater than 2-fold. The level of gene expression relative to normal breast tissues (mix of two) is shown by the colour and shade designated in the key at the bottom of the cluster. Each colour shade encompasses all of the values in the range spanned by the numbers beneath the scale. GenBank accession numbers (see Table 3) and descriptions for each gene, as well as the spot location on self-made arrays membranes are also provided. Confirmation studies were performed by Northern (AXL and GAS6, not shown for primary tumors) or RT-PCR analysis (Roche system only for HER2 expression and amplification, not shown) using the same RNA preparations used in the array. Unless otherwise noted, agreement between the arrays and other methods was within 2-fold, correlative for the majority of samples; qualitative agreement with array underestimating fold-change by other methodology by at least 10-fold.

**A.** Not supervised array analysis of the normal breast tissues, primary tumors, normal breast and cancer cell lines. AXL cluster is included 18

- 11 -

genes (the correlation of expression is 0,51 or significant) the most of these genes were identified in breast cancer cell lines (see Fig. 2).

**B. Classification primary tumors and breast cancer cell lines using only consensus invasiveness genes.** All primary tumors and BC cell lines were applied for cluster analysis using 26 genes (belongs to the AXL cluster). Primary tumors and BC cell lines were recognised and most highly invasive (HI) BC cell lines belong to the same tree (with the exception of MDA-MB-231 and one primary tumor BC151, indicated by red bar).

**Figure 4. Northern blot analyses of selected differentially expressed AXL/GAS genes.**

mRNA (15 µg/lane) isolated from each of the indicated cell lines was analyzed for expression of the designated genes by hybridization with probes corresponding to the fragments deposited on the cDNA arrays. Expression levels for each mRNA relative to Ac745 (normal breast epithelial cells) are recorded beneath each band. The sizes (at right) corresponding to the major specific bands agree with those reported in the literature for each mRNA. The same filters were used probed and re-probed for these analyses. Panel: **A** - expression AXL, **B** - GAS and **C** -β-actin mRNA. The levels of β-actin are shown for a representative filter as a control for equivalent sample load. mRNA was prepared from two independently grown cell cultures and tested for expression levels of the indicated genes.

**Figure 5A and B. Morphology of BC cell lines MDA-MB-435S, BT549 and MDA-MB-231 (mock) or stably expressing dnAXL when cultured on Matrigel.**

Cells were cultured on top of a Matrigel layer for 7–14 days.

**A**, photographs representing the three basic morphologies are shown for the indicated BC cell lines. **B**, Wound assays are shown for the MDA-MB-435S mock and dnAXL mutant clone 2. The position and treatment are indicated on the Fig. Magnification was x100.



- 12 -

**Figure 6A, B and C. 3D outgrowth, migratory and invasive behaviour of BC cell line MDA-MB-435S, mock, stably expressing dnAXL or after treatment with anti-Ex-AXL antibody.**

A. Cells were cultured on top of a Matrigel layer for 7–14 days (see legend to the Fig. 1). They were not treated or treated by antibody as indicated.

B. Invasive activities of the indicated BC cell line were measured in Boyden chambers by counting the number of cells that traversed the Matrigel (3–4 mg/ml)-coated filter in 20–36 h according to the procedure described in "Materials and Methods." Data are average values from at least two individual experiments containing triplicate points. Error bars.

C. Migration ability was assayed in parallel transwell chambers using filters without Matrigel under the same conditions as the invasion assay. Results shown are the averages of at least two experiments containing triplicate points (error bars). Cell migration was evaluated also in a Boyden chamber in the absence of the Matrigel barrier. As expected, cell lines MDA231, MDA435S, and BT549 were considerably more motile than the weakly invasive cell line MCF7 (not shown).

**Figure 7. Effect of AXL wt transfection on MCF7 breast cancer cells**

A. The morphological effects of AXL wt infection and forced over-expression. The over-expression of AXL wt in MCF7 cells results in a change from compact cobblestone-shaped cells to irregularly shaped cells with many protruding extensions.

B. The effects of AXL wt infection on cell invasion were assayed in a Boyden chamber assay as described above (see Material and Methods). The clones MCF7-AXL wt were up to 30-fold more invasive than the empty vector-infected cells.

- 13 -

A total of 20,000 cells were seeded on a Boyden chamber for 36-48 h (with filters pores 8  $\mu$ m, covered by matrigel matrix at concentration 3-4 mg/ml). Cells infected with AXL wt invade much sooner than cells infected with an empty vector control or dnAXL mutant form.

5

**Figure 8.**

A. Western blot analysis of SF126 glioma cell clones expressing the control vector (SF126-mock), the wild type form of UFO/AXL (SF126-Ufo-WT), and the truncated dominant-negative mutant form of UFO/AXL (SF126-Ufo-DN). Serum-depleted cells were left untreated (-) or treated with 200 $\mu$ g/ml Gas6 (+). Lysates were blotted with anti-phosphotyrosine serum (top panel) or an antibody directed against the extracellular domain of human UFO/AXL (lower row). Compared to SF126-mock cells the analyses demonstrated increased (approximately 30%) and abolished Gas6/UFO/AXL-mediated signalling in SF126-UFO-WT and SF126-UFO-DN cells, respectively. B-D. Expression of the truncated dominant-negative mutant form of UFO/AXL in SF126 cells (B) changed their morphology when compared to SF126-mock and SF126-UFO-WT cells (B and C).

20 **Figure 9.**

A. Analysis of tumor volume for SF126 cell clones. Tumor cells were implanted subcutaneously into nude mice (n=4 animals per group) and were followed for 14 days. The mean  $\pm$  SEM values are represented. \* p < 0.05 vs. SF126-mock cells. B. Quantitative analysis of tumor area (left panel) and functional vessel density (right panel) following implantation of SF126 cell clones into the dorsal skinfold chamber of nude mice, as assessed by intravital multi-fluorescence videomicroscopy (n=4 animals per group). The mean  $\pm$  SD values are represented. Statistical analysis was performed by ANOVA followed by the appropriate post hoc test for individual comparisons between groups; \* p < 0.05 vs. SF126-Ufo-DN cells. C and D. Representative histomorphological images of SF126-UFO-WT tumors (C) and SF126-UFO-DN tumors (D) showing differences in

25  
30

- 14 -

tumor volume. Bars indicate 1mm. H&E staining. E and F. Representative histomorphological images of SF126-UFO-WT tumors (E) and SF126-UFO-DN tumors (F) showing differences in tumor invasion. While SF126-UFO-WT tumors massively infiltrated the adjacent skin muscle and subcutaneous tissue (E) arrows indicate remnants of destroyed muscle layer), SF126-UFO-DN tumor cell invasion was almost completely inhibited (F). Note preserved structure of muscle layer in (F). Bars indicate 100 $\mu$ m. H&E staining. H and I. Fluorescence microscopy alone (G) and in combination with phase contrast (H) confirming lack of SF126-UFO-DN tumor cell invasion into adjacent tissue layers. Tumor cells were labeled with Dil prior implantation. Bars indicate 100 $\mu$ m. All specimens were excised on day 21 after implantation into the dorsal skinfold chamber of nude mice. t, tumor mass; m, skin muscle layer; sc, subcutaneous tissue. SF126-mock, controls; SF126-Ufo-WT, cells expressing the wild type form of UFO/AXL; SF126-Ufo-DN, cells expressing the truncated dominant-negative mutant form of UFO/AXL.

**Figure 10.**

A. MTT proliferation assay of SF126 cell clones. In absence and presence of Gas6 (200 $\mu$ g/ml). Cells were left untreated (-Gas6) or treated with 200 $\mu$ g/ml Gas6 (+Gas6). Analysis was performed after 48 hours of culture. Growth rate is expressed in relation to unstimulated SF126-mock cells. The mean values are represented. B and C. Formation of multicellular aggregates by SF126-Ufo-WT and SF126-Ufo-DN cell clones demonstrating unaltered -- ability to aggregate following inhibition of UFO/AXL function. D. Migration of SF126 cell clones over an observation period of 7 days. Area of migration was analyzed planimetrically by means of an image analysis system. The mean  $\pm$  SD values are represented. Statistical analysis was performed by using ANOVA followed by unpaired Student's t-test. \*  $p < 0.05$  vs. SF126-mock. E and F. Analysis of tumor cell invasion by 48 hour confrontation of SF126-UFO-WT tumor cell spheroids (E) or SF126-UFO-DN tumor cell spheroids (F) with fetal rat brain cell aggregates.

- 15 -

Clear-cut border between SF126-UFO-DN tumor cell spheroid and brain cell aggregate indicates lack of invasiveness following inhibition of UFO/AXL function. B, brain cell aggregate; S, tumor spheroid. SF126-mock, controls; SF126-Ufo-WT, cells expressing the wild type form of UFO/AXL; SF126-Ufo-DN, cells expressing the truncated dominant-negative mutant form of UFO/AXL.

### Figure 11.

A. Survival curve for adult nude mice following stereotactic implantation of SF126-Ufo-WT cells and SF126-Ufo-DN cells into the brain (n = 4 animals per group). Animals were sacrificed as soon as they developed neurological deficits or lost >30% of their initial body weight. B-E. Histomorphology of SF126-Ufo-WT tumors after implantation into the brain showing diffuse tumor cell infiltration into adjacent brain tissue (B). Tumor cells infiltrated via the perivascular space (C), along white matter tracts (D), and along the wall of the ventricular system (E). H&E staining. Bars indicate 100µm.

### Examples

#### A. Breast and prostate cancer studies

##### 1. Materials and methods

##### 1.1. Tumor samples and cell lines

To avoid any bias of selection as to the type and size of breast cancer (BC) and others tumors, the RNAs to be tested were prepared from unselected samples. Samples of primary invasive breast carcinomas were collected from 72 patients undergoing surgery. After surgical resection, the tumors were macrodissected: a section was taken for the pathologist's diagnosis and an adjacent piece was quickly frozen in liquid nitrogen for mRNA extractions. The median age of patients at the time diagnosis was 55 years (range 29-81) and most of them were postmenopausal. Tumors were

- 16 -

classified according to the WHO histological typing of breast tumors: ductal carcinomas, lobular carcinomas, mixed ductal-lobular carcinomas and medullary carcinomas. Pooled "normal" cDNA derived from normal breast mRNAs (3) was used as control and for normalisation. Expression profiles of protein kinases (PK) and phosphatases (PP) in "normal" cDNAs mentioned above were evaluated separately. In this study we also included 21 BC and 3 normal breast epithelial cell lines. The sources of the breast cancer cell lines were as follows: BT-20, BT-474, BT-483, BT-459, Du-4475, MDA-MB-134, -157, -175, -361, -436, -453, -468, SK-BR-3, and ZR-75-1, T-47D, MDA-MB-231, ZR-75-30 were obtained from the American Type Culture Collection (ATCC, Rockville, MD). MCF-7, clone and BC cell line DAL were supplied by SUGEN (Redwood City, CA). The HBL-100 cell line was from ATCC. This cell line was derived from normal tissue but contains tandemly integrated SV-40 sequences (9). Cultures were maintained in exponential growth in RPMI 1640 medium, supplemented with 6 mM glutamine, 10 µg/ml human insulin and 10% Fetal calf serum (FCS) (CSL, Parkville, Australia). Normal breast epithelial cell strains MCF10A, MCF10 T-24 and MCF10 neo were provided by Dr. B. Gilles (Arizona Cancer center). Ac745 was provided by Dr. M. Stampfer and grown in the DMEM F12 medium supplemented by the condition medium of Hs578Bst, Insulin, Hydrocortisone, EGF, Cholera toxin, vitamins and antibiotics.

Cells were free from Mycoplasma contamination.

## 1.2. Isolation and fractionation of RNA and DNA.

Total RNA and genomic DNA was isolated from the same cell pellet by lysis in guanidinium isothiocyanate solution (GTS buffer: 4 M guanidinium isothiocyanate, 25 mM sodium citrate pH 7.0, 0.5% Sarkosyl, and 0.1 M β-mercaptoethanol) followed by phenol-chloroform extractions. Total RNA was isolated using standard methods (Sambrook et al., [1989]) with modifications. DNA was collected and extracted twice with an equal

- 17 -

volume of phenol:chloroform:isoamylalcohol (25:24:1). RNA and DNA were isolated from each cell line on a minimum of 3 independent occasions.

Total and mRNA integrity and cDNA complexity was controlled by agarose gel electrophoresis and Northern blots using specific probes. Some mRNA extraction was performed using the OligoTex mRNA isolation Kit (Quagen, Biotech, Germany). Cell pellets were resuspended in lysis/binding buffer, vortex-mixed briefly, passed three times through a 21G needle and applied to a spin lysate column and centrifuged at 13,000g for 3 min. The lysate was then mixed gently with Oligo-dT cellulose (Stratagene Inc.) and applied to a pre-wetted Oligotex molecular biology column (Quagen Biotech). The column was washed three times with lysis/binding buffer and four times with wash buffer before eluting the mRNA with pre-warmed (65C) elution buffer. The quantity of mRNA was measured using the OD260.

### 1.3. cDNA arrays preparations

PK and PP gene expression was analyzed by hybridization on nylon filters arrays with radioactive targets (cDNA). The arrays contained 645 genes encoding kinases, phosphatases and others signalling proteins: ligands, adaptors, transcription factors, metalloproteinases/ADAMs, apoptosis related genes and 11 house keeping genes (the list is available at <http://www.biochem.mpg.de> or [ullrich@biochem.mpg.de](mailto:ullrich@biochem.mpg.de)). Their identity was verified by sequencing of plasmid DNA and compared with GenBank sequence information. Identity of PK and PP was conformed for all clones spotted on nylon filters ones, or in duplicate. For normalisation purpose, the GFP gene was spotted two times as well as genomic and vector DNA. Purification of plasmids was done using a plasmid purification kit (Qiagen, Germany).

### 1.4. cDNA array hybridization

Filters were initially pre-washed in 0.5% SDS for 5 min, with agitation. In 10 ml of the pre-hybridisation solution was included Yeast tRNA. Human

- 18 -

Cot-1 DNA (BRL/Life technologies) was used in the hybridization step which was performed in a Roller bottle (Hybaid Inc.) for 16 h in a roller oven at 65°C. Labelled probe was denatured for 10 min at 100°C and then placed immediately into the hybridisation mixture which was  
5 incubated for a further 18 h at 65°C. After 18 h, the hybridisation mixture was discarded and the array was washed twice in 2 sodium chloride: sodium citrate (SSC) buffer, 0.2% SDS for 20 min at 42°C with continued rotation in the incubator. A third wash was performed in 0.2xSSC, 0.1% SDS for 15-60 min at 65°C in a plastic box with horizontal shaking. After  
10 the third wash, the filter was placed on a piece of moistened Whatman paper and covered with Saran wrap. The array was then placed into an imager cassette with a Phosphorimager storage screen (Fuji, Japan) and exposed for 2 days.

#### 15 1.5. Image acquisition and analysis.

Exposed phospho-imager storage screens were scanned once on a Phosphoimager Scanner (Fuji) at a resolution of 50 microns and were visualised using MacBAS 2000 (Fuji). Images were imported into ArrayVision V(Canada) for analysis by a software protocol. Mapping of  
20 individual elements to an internal reference database was achieved by aligning the images onto a software-based matrix using a total of 4 control elements representing total genomic control DNA, GFP, and vector. Normalisation was performed by multiplying the raw intensity for each data element by a normalisation factor equal to the average raw intensity for all  
25 the vector elements divided by 100 (this value is the average raw intensity for all elements, derived from a large number of different hybridizations performed by us the development of the arrays). Software-based pair-wise comparisons of the normalised images were made against the image obtained from hybridisation of labelled cDNA taken from pooled "normal"  
30 cDNA derived from normal breast RNAs, immortal (preneoplastic) breast epithelial cell lines, as indicated above. Changes in expression levels were calculated using normalised intensities and given as ratios (positive ratios

indicated an increase in transcript levels, negative ratios indicated a decrease in transcript levels) and were visualised by Scatter-blot graphics and TreeView program (13-16).

## 5     **1.6. Array data analysis**

Before analysis of the results, the reproducibility of the experiments was verified by comparing duplicate spots, or one hybridizations with the same cDNA on two independent arrays, or two independent hybridizations with cDNA prepared from the same RNA. In each case, the results showed good  
10 reproducibility with respective correlation coefficients 0.96, 0.98 and 0.98 (data not shown). The reproducibility was sufficient enough to consider a 2-fold expression difference as significantly differential. Subsequent analysis was done using Excel and statistical software. The search for genes with expression levels correlated with tumor parameters was done  
15 in several successive steps. First, genes were detected by comparing their median expression level in the two subgroups of tumors differing according to parameters of interest. We used the median values rather than the mean values because of the high variability of the expression levels for many genes, resulting in a standard deviation expression level similar or superior  
20 to the mean value and making comparisons with means impossible. Second, these detected genes were inspected visually on graphics and, finally, an appropriate statistical analysis was applied to those that were convincing to validate the correlation. Comparison of HER2 expression between ER-positive tumors and ER-negative tumors was validated using a  
25 Mann-Witney test. Correlation coefficients were used to compare the gene expression levels with the number of axillary nodes involved.

## **1.7. Cluster analysis**

The data from this study were analyzed and displayed as described (13-  
30 16). Briefly, a hierarchical clustering algorithm produces a table of results wherein the elements/cDNAs of the array (representing specific genes) are grouped together based on similarities in their patterns of gene expression.



- 20 -

The same algorithm is applied to cluster the experimental samples (i.e., cell lines and tumors) according to the similarities in their overall patterns of gene expression. The data tables, thus ordered, are presented graphically as colored images. Along the vertical axis, the genes analyzed are arranged as ordered by the clustering algorithm, so that the genes with the most similar patterns of expression are placed adjacent to each other. Along the horizontal axis, experimental samples are similarly arranged such that those with the most similar patterns of expression across all genes are placed adjacent to each other. The colour of each cell/square in this tabular image represents the measured expression ratio of each gene in question. The colour saturation is also directly proportional to the magnitude of the measured gene expression ratio with the brightest red squares having the highest T/N ratio (i.e., >8-fold difference), the brightest green squares having the lowest T/N ratio, black squares indicating a ratio of approximately 1, and grey squares indicating insufficient data quality.

### 1.8. RNA analysis by Northern-blot

We used standard protocol of Northern-blot analysis for detection of the expression AXL and GAS6 genes in preparation of some breast cancers and all breast cancer cell lines. The loading RNA samples were verified by re-hybridization of filters with a human  $\beta$ -actin probe.

### 1.9. Chemoinvasion and Migration Assays

The chemoinvasion assay was carried out using a modification of the method of Albini et al. (10). After trypsinization, cells (20.000) were plated on Matrigel-coated (150  $\mu$ l of 4.0 mg/ml) 8- $\mu$ m polypropylene filter inserts in Boyden chambers (Biocoat Matrigel Invasion Chamber, Becton Dickinson, Bedford, MA or Nunc 10mm tissue culture inserts, Naperville, IL). The bottom chamber contained 0.55 ml of NIH3T3-conditioned media, produced as described by Albini et al. or normal growth media for some cell lines.

- 21 -

BC cell lines obtained from the ATCC were trypsinized, centrifuged, and resuspended at  $4 \times 10^5$  cells/ml in RPMI medium containing 10% FBS. The remaining cell lines were resuspended in their regular growth medium.

5 After 20-36 h, the cells remaining in the insert were removed with a cotton swab, and the cells on the bottom of the filter were counted using different protocols: fixed in Diff-quick (American Scientific Products, McGraw Park, IL) and treated with RNase A (at 50  $\mu$ g/ml for 20 min at 37°C) before staining with propidium iodide (10  $\mu$ g/ml in PBS) for 1 min at room  
10 temperature (RT). The dried filters were removed and mounted on slides with Cytoseal 60 mounting media (Stephens Scientific, Kalamazoo, MI). Individual propidium iodide-stained nuclei on the filters were counted. Most results were obtained using trypsinization and counting of the cells. Triplicate samples were counted in each experiment. Outlying values were  
15 eliminated from calculations of average invasive activity.

For invasion assays in presence of antibody, cells were seeded on Matrigel and, when attached, the indicated antibody was added to the medium. The antibody was present in the upper chamber for the entire duration of the  
20 assay; at the end of the assay, cell viability in the upper chamber was assessed by Trypan blue. Migration activity was determined following the procedure described for the invasion assay except that the cells were plated on top of uncoated 8- $\mu$ m pore polypropylene filters in the Boyden chambers.

25

#### 1.10. Matrigel Outgrowth

Determination of the morphology of cells grown on Matrigel was carried out as described previously (10). Briefly, cells (5000 cells/well of a 96-well plate) resuspended in 50  $\mu$ l of culture medium were plated on top of a pre-set Matrigel coating consisting of 70  $\mu$ l of Matrigel (Becton Dickinson)  
30 diluted to 6.0 mg/ml in -RPMI basal medium salts. After polymerization on the top of these diluted 50  $\mu$ l of Matrigel (1.0 mg/ml) were added. Colony

- 22 -

outgrowth was monitored over the course of the experiment and photographed at 7–14 days using a Zeiss AxioVert 35 microscope equipped with a OpenLab (UK) digital camera.

5     **1.11. Wound assay**

After overnight starvation, wounds were made on confluent cell monolayers with a plastic tip. MDA-MB-345S-mock and MDA-MB-435-dnAXL, clone 2 cells were treated with culture medium (10% FCS) and culture medium containing GAS6 (200 ng/ml) for 12, 24 and 48 h, before  
10     taking pictures (phase contrast). To quantify cell migration, three randomly chosen regions of a wound (1 mm long) were photographed at a magnification of 40X; a mean wound width was measured every 20  $\mu$ m, and an average percent wound closure was calculated. Three independent wounds were examined per sample and a mean percent wound closure was  
15     calculated.

**1.12. The treatment of cells with antibody**

Breast cancer cells (5000 for the 3D outgrowth assay and 20000 for the invasion assay in a Boyden chamber) were treated by Ex-AXL polyclonal  
20     antibody (200  $\mu$ g/ml) using 50  $\mu$ l of antibody and 500  $\mu$ l cell suspension. Cells were incubated with antibody 60 min at RT and then washed in PBS at RT. Plating of cells and the following 24 h treatment interval were performed with the same concentration of Ex-AXL antibody.

25     **1.13. Infection of BC cells with recombinant retroviruses**

AXLwt and dn-AXL mutant forms of the viruses were obtained according to a standard protocol (31) with modifications. Briefly, pLXSN-AXLwt and pLXSN-dnAXL were cloned via EcoRI/BamHI and NotI/XbaI sites, subsequently.

30

The packaging cell line Phoenix A was transfected with these vectors using calcium phosphate. The supernatant of transfected Phoenix A cells was

- 23 -

collected and filtered through a 0.45- $\mu$ m filter. for the infection of the human cancer cell line, cells were incubated with viral supernatant for 24 h. After 48 h, medium was replaced with medium containing 400  $\mu$ g/ml G148. For further selection, cells were incubated with G418 for 14 days.

5 Polyclonal and monoclonal cell lines were generated by limited dilution. AXL expression was monitored by Western blot and array analysis. Polyclonal and three monoclonal cell lines with similar expression levels of AXL wt and dn-AXL were chosen for further experiments.

#### 10 1.14. Antibodies

AXL/UFO-specific antibodies were generated by immunization of rabbits with recombinant GST-AXL extra-cellular domain fusion protein containing amino acid residues 1-410 (AXL-Ex). The recombinant GST-AXL-Ex protein was stably secreted by transfected HEK293 cells (vector pcDNA3-GST).

15 Culture medium was collected and GST-AXL-Ex protein purified using standard GST-tag protocol (Pharmacia, Sweden). AXL-Ex polyclonal antibodies were partially purified on GST-Sepharose affinity columns.

## 20 2. Results

The purpose of this study was to establish expression profiles of protein kinase, phosphatase and signalling genes in breast cancer cells with the objective of identifying novel markers for breast cancer aggressiveness. cDNA hybridization arrays were used to analyze the gene expression

25 profiles of 14 weakly, 7 highly invasive breast cancer cell lines and 3 normal breast epithelial cell lines (Table 1, Fig. 1, 3D growth of invasive BC cell lines and control).

**Table 1 Characteristics of the breast cancer cell lines used to generate the consensus of invasiveness**

5	Cell line	Specimen origin <i>a</i>	Tumorigenicity <i>b</i>	Matrigel morphology <i>c</i>
	Marker gene expression <i>d</i>			
		ER-	E-cad	Vim
<hr/>				
10	<u>Weakly invasive</u>			
	ZR-75-1			
	T47D	Infiltrating ductal Ca; PE	+e	Fused
	+	+	-	
	ZR75-1	Infiltrating ductal Ca; ascites	+e	Fused
	+	+	-	
15	MCF7	Breast adenocarcinoma; PE	+e	Fused
	+	+	-	
	MDA361	Breast adenocarcinoma; brain met	+e	Fused
	+	+	-	
	BT474	Invasive ductal Ca; PT	+e	Fused
	+	+	-	
	BT20	Breast adenocarcinoma: PT	+	Fused -
20	ND	-		
	MDA468	Metastatic adenocarcinoma; PE	+	Fused -
	-	-		
	SKBR3	Breast adenocarcinoma; PE	+	Spherical
	-	-		
	MDA453	Metastatic breast Ca; PE	-	Spherical
	-	-		
25	BT483			
	MDA175			
	Du44-75			
	DAL			
	ZR-75-30			
	HBL-100			
	<u>Highly invasive</u>			
30	MDA435S	Metastatic ductal adenocarcinoma +, met		Stellate
	-	-	+	
	BT549	Papillary invasive ductal Ca; PT	-	Stellate
	-	-	+	
	Hs578T	Ductal Ca; PT	+, met	Stellate
	-	-	+	

- 25 -

	MDA231	Breast adenocarcinoma: PE	+, met	Stellate
	-	-	+	
5	MDA436	in progress		Stellate
	MDA415	in progress		
	MDA157	in progress		Stellate

---

10 **Remarks:**

a) Specimen origin and pathological assessment information were obtained from the ATCC catalogue. PT, primary tumor; PE, pleural effusion; Ca, carcinoma.

15 b) Tumorigenicity data was reported in the ATCC catalogue or in Ref. 17.  
+, palpable tumors produced as xenografts in athymic nude or SCID mice;  
-, nontumorigenic; met, metastatic cell lines as reported by Refs. 18 and 19.

c) Description of the morphology of cells cultured in Matrigel and their  
20 activity in the Boyden chamber invasion assay was taken from Ref. 10.

cDNA microarray membranes, containing 650 genes were used in these studies. Differences in gene expression between weakly and highly invasive BC cells were identified that enabled the definition of "consensus  
25 of invasiveness" for each invasive phenotype (Fig. 2, Cluster AXL, correlation >0.71). Highly invasive BC cell lines (BT549, MDA-MB-231, MDA-MB-436, MDA-MB-415, Hs578T, MDA-MB-157 and MDA-MB-435S) over-expressed AXL and show a defined gene expression profile that discriminate them from weakly invasive BC cell lines and "normal" breast  
30 epithelial cells. These cluster included genes already known as markers of invasiveness (CD44, VIM, CAV1, 2 and MMPs (Ref. 20-27)). Some of these genes have only been considered for association with cancer cell

- 26 -

invasiveness (M-CSF and EPHA2 (Ref. 28-30) and Table 2). Other genes of the cluster were identified for the first time as genes associated with cancer cells aggressiveness: AXL, GAS, MMP14, Adam12, Adam17, MT3MMP, FGF2 and 5, Fyn, Lyn, DDR2, TIMP1, HB-EGF, SGK, S6KII, MAP4K4, SIRP $\alpha$  and Annexin 2.

Remarkably, no one of these BC cell lines did express estrogen receptor (see Fig. 3, as indicated for the BC cell lines characteristics). Cluster AXL of the co-expressed genes was identified in primary BC (Fig.3) and others tumors and cancer cell lines (kidney, prostate and glioblastomas) as well (data not shown). The expression of the AXL and GAS genes in invasive BC cell lines were conformed by Northern-blot hybridization (Fig. 4).

The dominant negative mutant of the AXL gene (dnAXL) which was stable over-expressed in highly invasive BC cell lines strongly suppressed invasiveness, migration and survival of the several BC cell lines: MDA-MB-435S, BT549 and partially MDA-MB-231 (Fig. 5A and B). All clones having stable dn-AXL expression had 3D-growth on the Matrigel matrix like non-invasive or weakly invasive breast cancer cell lines, for example, MCF7. The dn-AXL expression significantly inhibits GAS6 signalling and results in reduced or lacking AXL phosphorylation upon GAS treatment. ERK2 signalling in these cells was also blocked.

A polyclonal antibody directed against extracellular portion of AXL (containing amino acids residues 1-410, Ex-AXL) alters the cell morphology (Fig. 6A) and has very strong inhibitory activity on the migration and invasion of the MDA-MB-435S and BT549 BC cell lines (Fig. 6B and C). Similar results were obtained with the prostate cancer cell line PPC1. Moreover, over-expression of wild-type (wt) AXL in the weakly invasive BC cell line MCF7 and prostate cancer cell line LNCaP resulted in a transformation in to a highly invasive phenotype.

- 27 -

## B. Glioblastomas studies

### 1. Material and Methods

#### 5 1.1 Human glioma cells

The following human glioma cell lines were used in this study: U-118, U-1242, SF126, A-172, U-373, U-1240, T-98G, SF763, and SF767. All cells were grown in 10% fetal bovine serum (PAA GmbH, Linz, Austria) at 37°C in 5% CO<sub>2</sub> humidified incubators and tested routinely for  
10 Mycoplasma contamination with Hoechst 33258 stain. Growth media (all from Gibco, Karlsruhe, Germany) were used as follows: DMEM for U-118, T-98G, and SF763; MEM, nonessential amino acids (1:100 dilution of stock; Gibco), 1mM Na-Pyruvate for U-1242; DMEM with 4,5g/L Glucose for SF-126, A-172, and U373 and MEM for U-1240 and SF767. Prior to  
15 tumor implantation into the dorsal skinfold chamber preparation, cells were stained with Dil as previously described (Reference 35).

#### 1.2 cDNA Array Hybridization

The content of the cDNA array as well as its hybridization technique have  
20 been previously described in detail (Reference 31). The array comprised 125 cDNA fragments, corresponding to 84 RTKs and 30 protein tyrosine phosphatases, plus control cDNAs. Total RNA, Poly(A)<sup>+</sup> RNA, and cDNA probes were generated as described elsewhere (Reference 31). Labeling of 3-5 µl of cDNA was performed with the Megaprime kit (Amersham) in the  
25 presence of 50 µCi of [<sup>32</sup>-P]dATP. The prehybridization solution was replaced by the hybridization solution containing 5x SSC, 0.5% (v/v) SDS, 100 µg/ml baker yeast tRNA (Roche), and the labeled cDNA probe (2-5 x 10<sup>6</sup> cpm/ml) and incubated at 68°C for 16 h. Membranes were washed under stringent conditions. A phosphorimager system (Fuji BAS 1000; Fuji)  
30 was used to quantify the hybridization signals. Average values for each slot were calculated using the formula:  $A = (AB - B) \times 100/B$ ; [A, final volume; AB, intensity of each slot signal (pixel/mm<sup>2</sup>); B, background



- 28 -

(pixel/mm<sup>2</sup>)). Results of the cDNA array had to be confirmed by RT-PCR analysis as previously described (Reference 31).

### 1.3 Generation of expression constructs and stable cell lines.

5 The 2.7 kbp cDNA sequences coding for AXL were cloned into the EcoRI/BamHI restriction sites of the retroviral vector pLXSN. The dominant-negative variant was generated by subcloning the 1.5 kbp EcoRI/FspI fragment into the same vector. Expression plasmids and empty vector were transfected into Phoenix-Ampho cells using a calcium phosphate  
10 coprecipitation method. Supernatants containing recombinant retroviruses were harvested 28 h after transfection, mixed with polybrene at a final concentration of 8 µg/ml, and applied for 3 h to subconfluent SF126 cells. Infection was repeated twice with fresh supernatant of the same producer cells. Infected cells were passaged after one day and selected with 1  
15 mg/ml G418 for two weeks. Monoclonal cell lines were selected for high expression of AXL as monitored by western blot analysis.

### 1.4 Immunoprecipitation and Western Blotting

Cells were lysed in 50 mM Hepes pH 7.5, 150 mM NaCl, 1 mM EDTA,  
20 10% glycerol, 1% Triton X-100, 10 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> supplemented with 10 µg/ml Aprotinin, 1 mM PMSF, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 10 mM NaF. Protein concentrations were determined by the micro BCA protein assay (PIERCE, Rockford, Illinois). AXL was precipitated from 1.8 mg of total cellular proteins using 30 µl of protein A sepharose suspension (CL-4B, Amersham  
25 Biosciences, Freiburg, Germany) and 3 µl anti-AXL polyclonal rabbit serum (Reference 36) overnight at 4°C. Precipitates were washed three times with HNTG buffer (20 mM Hepes pH 7.5, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100). Immunoprecipitates or 200 µg of total cellular proteins per lane were mixed with reducing sample buffer, separated by 7.5% SDS-  
30 PAGE, and transferred to nitrocellulose membranes (Protran; Schleicher&Schuell, Dassel, Germany). Membranes were blocked with 0.25% gelatine in 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 5 mM EDTA,

- 29 -

0.05% Triton X-100 and incubated over night at  $-4^{\circ}\text{C}$  with anti-phosphotyrosin monoclonal antibody 4G10 diluted 1:5000 in the same buffer. Secondary antibody goat anti-mouse HRP (1:10000, BioRad) was applied for 60 min at room temperature. Membranes were stripped for 90 min at  $55^{\circ}\text{C}$  before reprobing with anti-AXL (polyclonal rabbit serum, 1:1000) and protein A-HRP (BioRad, 1:40000). Detection was performed with Western Lightning reagents (Perkin Elmer Life Sciences, Boston).

### 1.5 Mice

Athymic nude mice (nu/nu; male/female) were bred and maintained within a specific pathogen germ-free environment and were used at 6-10 weeks of age. Experiments were performed in accordance with the approved institutional protocol and the guidelines of the Institutional Animal Care and Use Committee. For surgical procedures mice were anaesthetised by s.c. injection of ketamin/xylazine.

### 1.6 Subcutaneous and orthotopic xenografts

Glioma xenografts were grown subcutaneously following injection of  $1 \times 10^6$  C6 cells (Reference 44) into the left flank regions of nude mice. Tumor growth was assessed using vernier calipers until day 14 after implantation. Tumor volume was calculated as  $(\text{length} \times \text{width} \times \text{height})/2$ . For intracerebral tumor cell implantation the head of nude mice was fixed in a stereotactic rodent head holder. Implantation was performed by injecting  $5 \times 10^5$  cells stereotactically in the right striatum. All animals were sacrificed as soon as animals in one experimental group developed neurological deficits or lost  $>30\%$  of their body weight in order to compare tumor growth.

### 1.7 Dorsal skinfold chamber model

Two symmetrical titanium frames flanked the dorsal skinfold of animals to sandwich the extended double layer of skin and create the dorsal skinfold chamber which consist of one layer of striated muscle, subcutaneous

- 30 -

tissue, and epidermis. An observation window, covered with a glass cover slip, allowed for repeated intravital microscopic observations of the microvasculature of the tumour growing in the chamber. Two days after chamber preparation, the coverslip of the dorsal skinfold chamber was temporarily removed for tumor cell implantation. The animals tolerated the skinfold chambers well and showed no signs of discomfort or changes in sleeping and feeding behavior.

### 1.8 Intravital multi-fluorescence microscopy

Intravital epi-fluorescence videomicroscopy was performed over 21 days following implantation (References 37, 38, 39). Dil-labeling of glioma cells allowed for precise delineation of the tumor from the adjacent host tissue as well as identification of individual tumor cells applying green light epi-illumination (520-570nm). Contrast enhancement with FITC-conjugated Dextran (MW = 150,000; 0.1 ml i.v) and use of the blue light epi-illumination (450-490nm) was applied to visualize individual blood vessels. Tumor growth was assessed by measurement of the tissue area covered by the fluorescently-labeled tumor mass. Analysis of the host and tumor microvasculature included the vessel density and the vascular diameter (Reference 37).

### 1.9 Histology

Upon completion of experiments, the glioma containing dorsal skinfold chamber preparations and brains were dissected free, and frozen in liquid nitrogen for histomorphological analysis. The sections were mounted on stubs, embedded in Tissue-Tek (Miles Laboratories Inc., Naperville, IL) and frozen in 2-Methylbutane (E.Merck, Darmstadt, Germany) cooled with liquid N<sub>2</sub>. Serial axial sections (5  $\mu$ m) were cut and mounted on slides pre-coated with gelatine (Sigma). The sections were stained with Harris Haematoxylin and Eosin G (Merck) according to standard procedures.

- 31 -

### 1.10 Proliferation Assay

Proliferation of glioma cell lines was assessed in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Boehringer Mannheim, Mannheim, Germany). Cells were seeded in 96-well tissue culture plates at a concentration of 3000 cells/well and were cultured for 48 hours either in the absence or in the presence of Gas6 (200 $\mu$ g/ml). Cells were then assayed for their abilities to reduce MTT dye to a colored formazan product, as an index of cell proliferation.

### 1.11 Migration assay

Glioma cell spheroids were produced by seeding  $5 \times 10^6$  cells in culture medium into a 75-cm<sup>2</sup> flask previously base coated with 1.0% Noble agar (DIFCO, Detroit, MI.). After 7-10 days in culture, spheroids with a diameter less than 300- $\mu$ m were chosen for the migration and invasion studies.

Glioma spheroids were placed in the middle of 24-well plates. The area covered by the tumor cells migrating out from the spheroid explant was used as an index of cell migration. Two orthogonal diameters of each explant area were measured daily using a phase contrast microscope over a 7 day period and the mean area covered by tumor cells was calculated.

Migration assays were performed in quadruplicate.

### 1.12 Invasion assay

Fetal rat brain cell aggregates were generated according to a standardized procedure, which was described previously (Reference 40). Briefly, 18-day-old BD IX rat fetuses were removed by cesarean section. The brains were carefully dissected, minced, and serially trypsinized. After centrifugation,  $1 \times 10^7$  cells (resuspended in medium) were seeded in agar-coated wells of a 24-well plate. After 2 days of reaggregation, spheroids were transferred to fresh wells (five to seven aggregates/well), where they matured for 18 to 21 days. By that time, mature brain aggregates had formed. Fetal rat brain aggregates and glioma spheroids represent standardized, primary, avascular brain and tumor masses that resemble brain and glioma tissues

- 32 -

in situ, thus providing a suitable model to investigate glioma cell migration and vascular-independent invasion in vitro. For the invasion assay, single mature brain aggregates (diameter = 250-300  $\mu\text{m}$ ) were placed into agar-coated 96 well plates. Single glioma spheroids of similar size were also transferred into the wells and brought in contact with the brain aggregates. The confrontations were cultured for 24 and 48h respectively, after which time they were harvested, fixed in paraformaldehyde and embedded into plastic resin for the preparation of semithin sections (2 $\mu\text{m}$ ). The sections were stained with Toluidine blue. The process of glioma cell invasion was assessed for the amount of rat brain aggregate remaining intact. Invasion assays were performed in quadruplicate.

### 1.13 Statistics

For analysis of differences between the groups, one-way analysis of variance (ANOVA) followed by the appropriate post hoc test for individual comparisons between the groups was performed. Results with  $p < 0.05$  were considered significant.

## 2. Results

### 2.1

To study the relevance of UFO/AXL in glioma cell biology a truncated, dominant-negative mutant form of human UFO/AXL lacking the intracellular RTK-bearing domain, was introduced into SF126 glioma cells (SF126-Ufo-DN) using a retroviral expression system. Cells transfected with an empty vector (SF126-mock) or human wild-type form of UFO/AXL (SF126-Ufo-WT) served as controls. Western blotting with an antibody directed against the extracellular domain of human UFO/AXL confirmed the high expression levels of the wild-type and truncated receptor in SF126-Ufo-DN cell clones (Fig. 8A low panel). To ascertain whether the expression of the truncated receptor blocked UFO/AXL signal transduction, the UFO/AXL receptor phosphorylation following stimulation with its ligand Gas6 was determined

- 33 -

(Fig.8A top lane). In SF126-mock cells, a moderated baseline signal was observed which increased upon Gas6 stimulation. In SF126-Ufo-WT, the Gas6-induced signal was increased. In contrast, in SF126-Ufo-DN cells, both baseline and Gas6-induced phosphorylation were almost completely suppressed.

Blocking of UFO/AXL signalling had profound effects on glioma cell morphology, under regular culture conditions and in the absence of its ligand. While SF126-mock and SF126-UFO-WT cells (Figs. 8B and C) displayed an elongated, spindle shaped morphology with multiple cell-to-cell contacts, SF126-UFO-DN cells were characterized by a round morphology and reduced cell-to-cell contacts (Fig. 8D). Also, SF126-UFO-DN cells appeared to have lost their ability to adhere well to plastic.

## 2.2

In order to study the relevance of UFO/AXL for tumor growth  $1 \times 10^6$  cells of each clone were implanted subcutaneously into the flank of adult nude mice. When compared to SF126-mock cells the tumorigenicity of SF126-Ufo-DN cells was dramatically impaired, resulting in a 97% reduced tumor growth (Fig. 9A). In contrast, tumor growth was slightly accelerated in SF126-Ufo-WT cells (Fig. 9A). In order to obtain a more detailed insight into the role of UFO/AXL in glioma cell biology in vivo, SF126-Ufo-WT cells and SF126-Ufo-DN cells were implanted into the dorsal skinfold transparent chamber model of adult nude mice. Following fluorescent labeling of tumor cells and systemic administration of fluorescent plasma markers, this model allows for a repeatable and non-invasive assessment of tumor growth, tumor cell behavior, tumor angiogenesis and tumor perfusion by intravital multi-fluorescence videomicroscopy. Using this approach the significance of UFO/AXL signalling for tumor growth could be confirmed.



- 34 -

In comparison to SF126-Ufo-WT tumors, expansion of SF126-Ufo-DN tumors was significantly suppressed (Fig. 9B). One mechanism by which UFO/AXL may influence tumor growth and expansion is its modulation of blood vessel function und nutritive blood supply to the tumor. This hypothesis is supported by recent studies suggesting that Gas6/UFO/AXL-mediated signalling may interfere with the coagulation cascade as well as with blood vessel formation and maturation (Reference 41, 42). To test this, the tumors' functional vessel density and microvessel diameter as markers of tumor angiogenesis and tumor perfusion were quantitatively analyzed. However, as illustrated in Figure 9B, these analyses failed to support a vascular explanation (e.g. anti-angiogenesis, perfusion failure due to tumor vessel thrombosis) for the dramatic inhibition of SF126-Ufo-DN tumor growth.

The histomorphological analysis of the tumor specimens further emphasized the hypothesis that UFO/AXL signalling plays a central role for glioma cell biology. As demonstrated in Figs. 9 C and E, SF126-Ufo-WT tumors were characterized by a large solid tumor mass as well as massive invasion and subsequent destruction of the adjacent host tissue (i.e. muscle and subcutaneous tissue) by individual tumor cells. In contrast, SF126-Ufo-DN tumors were much smaller and failed to invade into the surrounding host tissues (Figs. 9 D and F). This lack of SF26-Ufo-DN tumor invasion tissue was further confirmed by fluorescence and phase contrast microscopy of frozen sections demonstrating lack of Dil-labeled SF126-Ufo-DN cells within the adjacent tissue (Figs. 9 G and H).

### 2.3

In order to further reveal the mechanisms underlying suppression of tumor growth via blocking of UFO/AXL function, glioma cell behavior *in vitro* was analyzed. MTT assays demonstrated that proliferation of SF126-Ufo-DN cells under regular culture conditions was reduced by 50% and 35% when compared to SF126-mock and SF126-Ufo-WT cells, respectively

- 35 -

(Fig. 10A). Noteworthy, this result was independent of stimulation with the UFO/AXL ligand Gas6, which confirms the previous hypothesis that Gas6/Ufo/AXL signalling does not exert a mitogenic activity. Since UFO/AXL has been suggested to mediate cell-cell adhesion (Reference 43) the cells' ability to form multicellular aggregates was also studied. SF126-mock and SF126-Ufo-WT cells readily formed spheroids (Fig. 10B). Their ability to aggregate was not attenuated in SF126-Ufo-DN cells (Fig. 10C) which confirms that cell aggregation is mediated solely by the extracellular domain of UFO/AXL, independent of the tyrosine kinase domain. Next, glioma cell migration was addressed by plating the tumor spheroids and measuring the distance of migrating tumor cells from the originating spheroid over time. While SF126-mock and SF126-Ufo-WT cells migrated comparable distances, tumor cell migration was severely impaired in SF126-Ufo-DN cells (Fig. 10D). Since cell migration is a prerequisite for tumor invasion the invasiveness of the SF126 cell clones was finally addressed by confronting tumor spheroids with fetal rat brain cell aggregates. Following 48 hours of co-culture, both SF126-mock and SF126-Ufo-WT cells had diffusely invaded the brain aggregate (Fig. 10E). In contrast, after the same time period a clear border between the SF126-Ufo-DN tumor spheroid and the brain cell aggregate could be observed, indicating that these cells were unable to invade into normal brain tissue (Fig. 10F).

Collectively, the histomorphology of the tumor xenografts and the present *in vitro* results provided clear evidence that UFO/AXL significantly modulates growth, migration and invasion of glioma cells and that inhibition of UFO/AXL signalling suppresses tumor expansion by blocking tumor cell growth and invasion into the adjacent tissue. To test the ability of UFO/AXL for being a novel target for the treatment of malignant glioma SF126-Ufo-WT cells and SF126-Ufo-DN cells were implanted into the brains of adult nude mice and their survival was assessed. Animals were sacrificed as soon as they developed neurological deficits or lost >30% of





- 36 -

their initial body weight. SF126-Ufo-WT tumors were characterized by an aggressive clinical course in that all animals had to be sacrificed within 8 days due to a rapid clinical deterioration (Fig. 11A). In contrast, animals bearing SF126-Ufo-DN tumors survived for the same observation period  
5 symptom-free and without weight loss (body weight day 0 =  $29 \pm 2$  g versus body weight day 8 =  $28 \pm 1$  g) (Fig. 11A). The histomorphological analysis revealed that SF126-Ufo-WT cells had diffusely infiltrated the brain parenchyma while the space occupying effect of the solid tumor mass was only moderate (Fig. 11B). Here, the typical means of human tumor cell  
10 invasion could be observed: along the perivascular space (Fig. 11C), along white matter tracts (Fig. 11D), and along the wall of the ventricular system (Fig. 11E). In contrast, SF126-Ufo-DN tumor formation could not be identified in any of the animals.

## 2.4 Summary

In summary, the results of the present analyses suggest a novel fundamental role for the RTK UFO/AXL in the biology of malignant brain tumors. The findings indicate that UFO/AXL is overexpressed by a significant number of human glioma cell lines, to an extent that is  
20 comparable to EGFR or PDGFR- $\alpha$ , and that it mediates glioma growth as well as glioma invasion. So far, UFO/AXL is the first RTK reported to be involved in glioma invasion and, therefore, represents a novel therapeutic target for interfering with these highly aggressive, as yet therapy-refractory, tumors. This is supported by the present results which  
25 demonstrate that inhibition of UFO/AXL signalling suppresses glioma growth and prolongs survival following orthotopic implantation.

In order to study the biological function of UFO/AXL this complex ability of human glioma cells to interact with each other and the matrix was  
30 analyzed in detail. As a result it could be demonstrated that inhibition of UFO/AXL function by expressing a truncated dominant-negative receptor mutant almost completely suppresses the cells' ability to migrate and to

- 37 -

invade into healthy brain tissue. It should be noted that the mutant form of UFO/AXL that was utilized in the present experiments lacked the intracellular domain, with the extracellular domain still being functionally intact. Consequently, UFO/AXL does not mediate tumor cell invasion simply through an interaction of the receptor with the matrix, but rather through involving the complex signalling cascade downstream the receptor. Furthermore, the present results also suggest that UFO/AXL is involved in tumor cell proliferation, potentially again through modulating cell-cell and cell-matrix interactions.

The central nervous system is characterized by a prominent expression of UFO/AXL, its ligand Gas6, and related RTKs, such as Tyro 3 or Mer. The findings of the present study now indicate that Gas6/UFO/AXL signalling may be part of the molecular system orchestrating migration and guidance of neurons and glial cells. Furthermore, the prominent expression of UFO/AXL and its ligand Gas6 by both the host and tumor tissue may provide a clue to a better understanding of the unique invasive capacity of tumors originating within the brain.

### C. Discussion

The fact that RTK AXL as a single gene is sufficient to induce tumor metastasis in experimental systems is surprising, because it stands in contrast to the current view that the acquisition of a metastatic phenotype is a multistep process involving several genetic and epigenetic events.

Both benign and malignant tumours grow in an uncontrolled way. But only cells of malignant tumours invade surrounding tissues and travel to distant organs (metastasize). An understanding of the molecular basis for this aggressiveness could lead to therapies that block the transition of a tumour from benign to malignant, and keep local disease in check. We have now identified proteins called AXL and GAS as a receptor-ligand pair in a

- 38 -

molecular checkpoint that regulates not only the invasiveness but also the surviving and movement of tumour cells - the trio of characteristics required for metastasis. The dn-AXL/GAS6 complex also suppresses tumor cells anti-apoptotic capability.

5

The present data show that GAS treatment of the BT-549 cells (stable expression of dn-AXL) in the presence of serum is not able to induce activation of ERK1/2 MAPK. Thus, this signalling pathway is effectively blocked AXL suppression.

10

In summary, the present data have shown that AXL/GAS play a key role in human cancers by influencing tumor cell invasion. AXL protein is a new target for cancer diagnosis and treatment (anti-invasiveness). For example, expression of dnAXL in cancer cells can prevent them from invasion and development of metastases. Further, genes of AXL-cluster (listed in Tab. 2) can be used as diagnostic tool for the detection of the pre-invasive stage development in primary tumours, particularly in primary tumours of breast, prostate, kidney and glioblastomas.

15

#### 20 D. Conclusions

25

1. Using cDNA array analysis of BC cell lines, primary tumors and glioblastoma cells a "consensus of invasiveness" (cluster AXL) has been identified. This consensus of invasiveness, comprising 32 genes, can be used to predict the aggressiveness of cancer cells and primary tumors.

30

2. A dominant negative mutant of AXL (dn-AXL) strongly suppresses the invasion of highly invasive breast cancer cell lines and also increases their sensitivity to serum withdrawal (apoptosis). A polyclonal antibody directed against extracellular portion of AXL (containing amino acids residues 1-410, Ex-AXL), is able to suppress the aggressiveness of the treated cancer cells.

- 39 -

3. RTK AXL as a single gene is sufficient to induce breast cancer cell invasiveness in experimental systems (see 2 and data on model systems BC - MCF7-wt AXL and prostate cancer cell line - LNCaP-wt AXL). This result is in contrast to the current view that the acquisition of a metastatic phenotype is a multistep process involving several genetic and epigenetic events.

4. RTK AXL is a good candidate for "Signal-transduction therapy" treatment strategies in which key pathways for hyperactive cellular signalling that cause cancer invasiveness and metastasis are targeted. The suppression of AXL signalling function by a dn-AXL mutant and/or by treatment with an inhibitory antibody cannot be bypassed by collateral or compensatory pathways.

5. Suppression of AXL gene expression in tumor therapy may be carried out by inhibition of AXL on the gene or transcript level, e.g. gene transfer of mutants, antisense molecules, ribozymes, siRNA, RNAi, or AXL gene expression suppressors or on the protein level, e.g. by low molecular weight AXL kinase inhibitors, AXL analogues, e.g. Ex-AXL fusion proteins such as a fusion of Ex-AXL with an JgG1 Fc fragment (ref. 32) or inhibitory antibodies. Further, suppression of AXL gene expression may be effected by AXL signal inhibitors, e.g. downstream inhibitors.

**Tab. 2**      **Consensus of invasiveness**

Breast cancer cell lines and control	
No	Genes of AXL cluster
Known function or involvement	
1	AXL/GAS
2	HBEGF
3	EPHA2
4	S6KII
5	SGK
6	ADAM17
7	Lyn/Fyn
8	MAP4K4
9	CD44/META1
10	ADAM12
11	Caveolin 1, 2
12	M-CSF
13	MMP14
14	Vimentin
15	SIRP alpha

proliferation, adhesion, antiapoptotic function, not yet associated with invasion

heparin-binding EGF

involved in breast cancer, prostate cancer, melanomas, glioblastomas vascularization

STK, ribosomal S6 kinase 2, not yet associated with invasion

STK, glucocorticoid-regulated kinase, antiapoptotic function, involved in survival of cells

TACE involved in shedding of TNF alpha receptor

SRC-family kinases

STK, activates JNK (but not p38 and ERKs), may be involved in TNFalpha signalling, similar to SLK

marker of cancer cells invasiveness

interacts with integrins, coexists with SRC and GRB2 in membrane ruffles, cytopl. domain involved in signalling via SH3

key role in signalling, associated with cell transformation, promote cell invasion

ligand for CSF-R1, vasculogenesis, constitutively expressed by invasive breast cancer cells

unic expression in endothelial cells, specific for CD44 shedding

associated with cell transformation, promotes cell migration and invasion, marker of epithelial-mesenchymal transition of cancer cells

adhesion, signalling, migration, involvement in invasion is unknown

Tabl.3.

NO	Spot labels(HUGO classification)	Accession	GenBank/Link	Publication
1	AXL (AXL receptor, tyrosine kinase)	M76125	M76125	Mol. Cell. Biol. 11 (10), 5016-5031 (1991)
2	ADAM12 (a disintegrin and metalloproteinase domain 12=meltrin alpha)	AF023476	AF023476	J. Biol. Chem. 273 (1), 157-166 (1998)
3	ADAM17 (a disintegrin and metalloproteinase domain 17=TACE)	U69611	U69611	Nature 385 (6618), 729-733 (1997)
4	ANXA2 (Annexin A2, p35 src-binding)	D00017	D00017	Cell 46 (2), 191-199 (1986)
5	CAV1 (caveolin 1, caveolae protein, 22kD)	Z18951	Z18951	FEBS Lett. 314 (1), 45-48 (1992)
6	CAV2 (caveolin 2)	AF035752	AF035752	Proc. Natl. Acad. Sci. U.S.A. 93 (1), 131-135 (1996)
7	CD44 (antigen= involved in matrix adhesion)	X66733	X66733	J. Invest. Dermatol. 99, 381-385 (1992)
8	DDR2 (discoidin domain receptor family, member 2)	X74764	X74764	Oncogene 8 (12), 3433-3440 (1993)
9	FGF2 (fibroblast growth factor 2 (basic))	NM002006	NM 002006	EMBO J. 5 (10), 2523-2528 (1986)
10	FGF5 (fibroblast growth factor 5)	NM004464	NM 004464	Mol. Cell. Biol. 8 (8), 3487-3495 (1988)
11	EPHA2 (EphA2=ephrin type-a receptor 2L)	M59371	M59371	Mol. Cell. Biol. 10 (12), 6316-6324 (1990)
12	GAS6 (AXL ligand, growth arrest-specific 6)	L13720	L13720	Mol. Cell. Biol. 13 (8), 4976-4985 (1993)
13	FRK (fyn-related kinase)	U00803	U00803	Gene 138, 247-251 (1994)
14	(HB-EGF)DTR (heparin-binding epidermal growth factor-like growth factor)	NM001945	NM 001945	Science 251, 936-939 (1991)
15	LYN (tyrosine-protein kinase)	M16038	M16038	Mol. Cell. Biol. 7 (1), 237-243 (1987)
16	PTPNS1 (PTP, non-receptor type substrate 1)	Y10375	Y10375	Nature 386 (6621), 181-186 (1997)
17	MMP1 (matrix metalloproteinase 1=interstitial collagenase)	M13509	M13509	J. Biol. Chem. 261, 6600-6605 (1986)
18	MMP14 (matrix metalloproteinase 14 (membrane-inserted))	NM004995	NM 004995	Nature 370 (6484), 61-65 (1994)
19	MMP2 (matrix metalloproteinase 2, gelatinase A)	NM004530	NM 004530	J. Biol. Chem. 263, 6579-6587 (1988)
20	MMP9 (matrix metalloproteinase 9=gelatinase B)	NM004994	NM 004994	J. Biol. Chem. 264 (29), 17213-17221 (1989)
21	MAP4K4(mitogen-activated protein kinase kinase kinase 4)	XM038748	NT 022171	Direct Submission
22	MT3MMP, or MMP16 (matrix metalloproteinase 16 (membrane-inserted))	NM005941	XM 042409	J. Biol. Chem. 270 (39), 23013-23020 (1995)
23	TIMP1 (tissue inhibitor of metalloproteinase 1)	NM003254	NM 003254	Nature 315 (6022), 768-771 (1985)
24	VIM (vimentin)	X56134	X56134	Nucleic Acids Res. 18 (22), 6692 (1990)
26	SGK (serum/glucocorticoid regulated kinase)	Y10032	Y10032	Proc. Natl. Acad. Sci. U.S.A. 94(9), 4440-4445 (1997)
26	RPS6KB1 (ribosomal protein S6 kinase, 70kD, polypeptide 1)	M60724	M60724	Mol. Cell. Biol. 11, 5541-5550 (1991)
27	FYN (proto-oncogene tyrosine-protein kinase (syn	M14333	M14333	Proc. Natl. Acad. Sci. U.S.A. 83, 5459-5463 (1986)

Table 4. Expression of EGFR and UFO/Axl in human glioma cell lines as assessed by tyrosin kinase cDNA array

cell line	EGFR	UFO/Axl	UFO/Axl : EGFR
U-118	169	1793	10.6
U-1242	324	1793	5.5
SF126	296	1612	5.4
A-172	438	1935	4.4
U-373	56	190	3.4
U-1240	139	262	1.9
T-98G	540	800	1.5
SF763	5526	39	0.0
SF767	1039	--	0.0

## REFERENCES

1. J.W. Janssen, A.S. Schulz, A.C. Steenvoorden et al., A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6 (1991), pp. 2113-2120.  
5
2. J. O'Bryan, R.A. Frye, P.C. Cogswell et al., AXL, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 11 (1991), pp. 5016-5031.  
10
3. Healy, A. M., Schwartz, J. J., Zhu, X., Herrick, B. E., Varnum, B., Farber, H. W. (2001). Gas 6 promotes AXL-mediated survival in pulmonary endothelial cells. Am. J. Physiol. 280: 1273L-1281  
15
4. A. Neubauer, A. Fiebeler, D.K. Graham et al., Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 84 (1994), pp. 1931-1941.
- 20 5. P. McCloskey, J. Pierce, R.A. Koski, B. Varnum and E.T. Liu , Activation of the AXL receptor tyrosine kinase induces mitogenesis and transformation in 32D cells. Cell Growth Differ. 5 (1994), pp. 1105-1117.
- 25 6. P. Bellosta, Q. Zhang, S.P. Goff and C. Basilico , Signalling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene 15 (1997), pp. 2387-2397.



- 44 -

7. S. Goruppi, E. Ruaro and C. Schneider , Gas6, the ligand of AXL tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. *Oncogene* 12 (1996), pp. 471-480.
- 5 8. P. McCloskey, Y.W. Fridell, E. Attar et al., GAS6 mediates adhesion of cells expressing the receptor tyrosine kinase AXL. *J. Biol. Chem.* 272 (1997), pp. 23285-3291.
- 10 9. Caron de Fromentel C., Nardeux P. C., Soussi T., Lavialle C., Estrade S., Carloni G., Chandrasekaran K., Cassingena R. Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbors SV40 genetic information. *Exp. Cell Res.*, (1985), 160: 83-94.
- 15 10. Albin A., Iwamoto Y., Kleinman H. K., Martin G. R., Aaronson S. A., Kozlowski J. M., McEwan R. N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. *Cancer Res.*, 47: 3239-3245, 1987.
- 20 11. Thompson E. W., Paik S., Brunner N., Sommers C. L., Zugmaier G., Clarke R., Shima T. B., Torri J., Donahue S., Lippman M. E., et al Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. *J. Cell. Physiol.*, 150: 534-544, 1992.
- 25 12. Terranova V. P., Hujanen E. S., Martin G. R. Basement membrane and the invasive activity of metastatic tumor cells. *J. Natl. Cancer Inst. (Bethesda)*, 77: 311-316, 1986.

- 45 -

13. Perou C. M., Jeffrey S. S., van de Rijn M., Rees C. A., Eisen M. B.,  
Ross D. T., Pergamenschikov A., Williams C. F., Zhu S. X., Lee J.  
C., Lashkari D., Shalon D., Brown P. O., Botstein D. Distinctive gene  
expression patterns in human mammary epithelial cells and breast  
cancers. *Proc. Natl. Acad. Sci. USA*, 96: 9212-9217, 1999.
14. Perou C. M., Sorlie T., Eisen M. B., van de Rijn M., Jeffrey S. S.,  
Rees C. A., Pollack J. R., Ross D. T., Johnsen H., Akslen L. A.,  
Fluge O., Pergamenschikov A., Williams C., Zhu S. X., Lonning P.  
E., Borresen-Dale A. L., Brown P. O., Botstein D. Molecular portraits  
of human breast tumours. *Nature (Lond.)*, 406: 747-752, 2000.
15. Johnston M. Gene chips: array of hope for understanding gene  
regulation. *Curr. Biol.*, 8: R171-174, 1998.
16. Duggan D. J., Bittner M., Chen Y., Meltzer P., Trent J. M.  
Expression profiling using cDNA microarrays. *Nat. Genet.*, 21:  
10-14, 1999.
17. Price J. E., Polyzos A., Zhang R. D., Daniels L. M. Tumorigenicity  
and metastasis of human breast carcinoma cell lines in nude mice.  
*Cancer Res.*, 50: 717-721, 1990.
18. Sommers C. L., Byers S. W., Thompson E. W., Torri J. A., Gelmann  
E. P. Differentiation state and invasiveness of human breast cancer  
cell lines. *Breast Cancer Res. Treat*, 31: 325-335, 1994.
19. Deborah A. Zajchowski, Marty F. Bartholdi, Yan Gong, Lynn  
Webster, Hsiao-Lai Liu, Alexander Munishkin, Catherine Beauheim,  
Susan Harvey, Stephen P. Ethier and Paul H. Johnson. Identification  
of Gene Expression Profiles That Predict the Aggressive Behavior of  
Breast Cancer Cells. *Cancer Research* 61, 5168-5178, July 1, 2001.

- 46 -

20. A. Wimmel, M. Schilli, U. Kaiser et al., Preferential histiotypic expression of CD44-isoforms in human lung cancer. *Lung Cancer* 16 (1997), pp. 151-172.
- 5 21. Subburaj Ilangumaran, Anne Briol, and Daniel C. Hoessli. CD44 Selectively Associates With Active Src Family Protein Tyrosine Kinases Lck and Fyn in Glycosphingolipid-Rich Plasma Membrane Domains of Human Peripheral Blood Lymphocytes . *Blood*, Vol. 91 No. 10 (May 15), 1998: pp. 3901-3908
- 10 22. Domagala W., Lasota J., Bartowiak J., Weber K., Osborn M. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. *Am. J. Pathol.*, 136: 219-227, 1990.
- 15 23. Domagala W., Wozniak L., Lasota J., Weber K., Osborn M. Vimentin is preferentially expressed in high-grade ductal and medullary but not in lobular breast carcinomas. *Am. J. Pathol.*, 137: 1059-1064, 1990.
- 20 24. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T, Hamaguchi M. Invasion activating caveolin-1 mutation in human scirrhou breast cancers. *Cancer Res* 2001 Mar 15;61(6):2361-4.
- 25 25. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. *Clin Cancer Res* 1998 Aug;4(8):1873-80.
- 30

- 47 -

26. Bachmeier BE, Nerlich AG, Lichtinghagen R, Sommerhoff CP. Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. *Anticancer Res* 2001 Nov-Dec;21(6A):3821-8.
- 5 27. Sounni NE, Devy L, Hajitou A, Franken F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM, Noel A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. *FASEB J* 2002 Apr;16(6):555-64.
- 10 28. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. *J Exp Med* 2001 Mar 19;193(6):727-40.
- 15 29. Pederson L, Winding B, Foged NT, Spelsberg TC, Oursler MJ. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. *Cancer Res* 1999 Nov 15;59(22):5849-55.
- 20 30. Kelly Carles-Kinch, Katherine E. Kilpatrick, Jane C. Stewart and Michael S. Kinch . Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior. *Cancer Research* 62, 2840-2847, May 15, 2002.
- 25 31. Bange J., Prectl D., Cheburkin Y., Specht K., Harbeck N., Schmitt M., Knyazeva T., Muller S., Gartner S., Sures I., Wang H., Imyanitov E., Haring HU, Knyazev P., Iacobelli S., Hofler H., Ullrich A. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. *Cancer Res.* 2002, Feb. 1, 62(3), 840-7.

- 48 -

32. Yanagita M., Arai H., Ishii K., Nakano T., Ohashi K., Mizuno K., Varnum B., Fukatsu A., Doi T., Kita T. Gas6 regulates mesangial cell proliferation through AXL in experimental glomerulonephritis. *Am. J. Pathol.*, 2001 Apr., 158(4), 1423-32.
- 5 33. Attar E.C, Fridell Y.C, Xu L., Jin Y., Maia D.M., Schell M.J., and Liu E.T. AXL receptor tyrosine kinase expression in human breast cancer. *Breast Cancer Research and Treatment*, (Oct., 1997) Vol. 46, No. 1, pp. 91.
- 10 34. Dodge Zantek N., Walker-Daniels J., Stewart J., Hansen R. , Robinson D., Miao H., Wang B., Kung H-J., Bissell M. J. and Kinch M. MCF-10A-neoSt: A New Cell System for Studying Cell-ECM and Cell-Cell Interactions in Breast Cancer. *Clinical Research*, Vol. 7, 3640-3548, November 2001.
- 15 35. Vajkoczy, P., Goldbrunner, R., Farhadi, M., Vince, G., Schilling, L., Tonn, J. C., Schmiedek, P., and Menger, M. D. Glioma cell migration is associated with glioma-induced angiogenesis in vivo, *Int J Dev Neurosci.* 17: 557-63, 1999.
- 20 36. Sasaki, T., Knyazev, P. G., Cheburkin, Y., Gohring, W., Tisi, D., Ullrich, A., Timpl, R., and Ho-henester, E. Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains, *J Biol Chem.* 277: 44164-70., 2002.
- 25 37. Vajkoczy, P., Schilling, L., Ullrich, A., Schmiedek, P., and Menger, M. D. Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence micro-scopic approach in the athymic nude mouse, *J Cereb Blood Flow Metab.* 18: 510-520, 1998.
- 30

- 49 -

38. Vajkoczy, P., Farhadi, M., Gaumann, A., Heidenreich, R., Erber, R., Wunder, A., Tonn, J. C., Menger, M. D., and Breier, G. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2, J Clin Invest. 109: 777-85., 2002.
39. Read, T. A., Farhadi, M., Bjerkvig, R., Olsen, B. R., Rokstad, A. M., Huszthy, P. C., and Vajkoczy, P. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells, Cancer Res. 61: 6830-7., 2001.
40. Bjerkvig, R., Laerum, O. D., and Mella, O. Glioma cell interactions with fetal rat brain aggregates in vitro and with brain tissue in vivo, Cancer Res. 46: 4071-9., 1986.
41. Stitt, T. N., Conn, G., Gore, M., Lai, C., Bruno, J., Radziejewski, C., Mattsson, K., Fisher, J., Gies, D. R., Jones, P. F., and et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases, Cell. 80: 661-70., 1995.
42. Fridell, Y. W., Villa, J., Jr., Attar, E. C., and Liu, E. T. GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells, J Biol Chem. 273: 7123-6., 1998.
43. Bellosta, P., Costa, M., Lin, D. A., and Basilico, C. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding, Mol Cell Biol. 15: 614-25., 1995.
44. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (Lond.) 367: 576-579.

- 50 -

### Claims

- 5 1. A method of determining the invasivity of malignant disorders comprising measuring the expression of at least one gene selected from the group consisting of AXL, GAS, MMP14, ADAM12, ADAM17, MT3MMP, FGF2, FGF5, FYN, LYN, DDR2, TIMP1, HB-EGF, SGF, S6KII, MAP4K4, SIRP $\alpha$ , Annexin 2, Stat 5b and EDG2 wherein a high expression correlates with a high invasivity.
- 10 2. The method of claim 1, comprising measuring the expression of at least two genes selected from said group.
- 15 3. The method of claims 1 or 2 comprising measuring the expression of at least the AXL gene.
- 20 4. The method of any one of claims 1 - 3, wherein the malignant disorder is cancer, particularly selected from breast cancer, prostate cancer, kidney cancer, lung cancer, colon cancer, glioblastomas and other cancers.
5. The method of claim 4, wherein the cancer is glioblastomas.
- 25 6. The method of any one of claims 1-5, wherein the expression is determined on the mRNA level.
7. The method of claim 6, wherein the expression is determined on a nucleic acid array.
- 30 8. The method of any one of claims 1-5, wherein the expression is determined on the protein level.

- 51 -

9. The method of claim 8, wherein the expression is determined by an immunoassay.
10. A method of reducing the invasivity of malignant disorders comprising inhibiting the AXL gene expression and/or AXL ligand gene expression and/or protein function and/or protein ligand function.
11. The method of claim 10, wherein the AXL protein ligand is GAS6.
12. The method of claim 10 comprising inhibiting the receptor tyrosine kinase activity of the AXL protein.
13. The method of claim 10 comprising inhibiting the expression of the AXL gene.
14. The method of claim 10 comprising inhibiting the interaction between the AXL protein and its ligands.
15. The method of any one of claims 10-14 comprising the administration of an inhibitor of the AXL gene, AXL ligand gene, AXL protein and/or AXL protein ligand in an amount which is effective of reducing the invasivity of malignant disorders to a subject in need thereof.
16. The method of claim 15, wherein the malignant disorder is cancer, particularly selected from breast cancer, prostate cancer, kidney cancer, lung cancer, colon cancer, glioblastomas and other cancers.
17. The method of claim 16, wherein the cancer is glioblastomas.



- 52 -

18. The method of any one of claims 15-17, wherein the subject is a mammal, particularly a human.
- 5 19. The method of any one of claims 15-18, wherein the inhibitor is an antibody directed against the AXL protein.
20. The method of any one of claims 15-18, wherein the inhibitor is an antisense nucleic acid, a ribozyme or an RNA interference molecule directed against the AXL gene or a transcript thereof.
- 10 21. The method of any one of claims 15-18, wherein the inhibitor is a dominant-negative mutant of the AXL gene.
- 15 22. A pharmaceutical composition comprising as an active agent an inhibitor of the AXL gene, AXL ligand gene, AXL protein and/or AXL protein ligand together with pharmacologically active diluents, carriers and/or adjuvants.
- 20 23. The composition of claim 22, wherein the inhibitor is an antibody directed against the AXL protein.
- 25 24. The composition of claim 22, wherein the inhibitor is an antisense nucleic acid, a ribozyme or an RNA interference molecule directed against the AXL gene or a transcript thereof.
- 25 25. The composition of claim 22, wherein the inhibitor is a dominant-negative mutant of the AXL gene.
- 30 26. The composition of any one of claims 22-25 for reducing the invasivity of malignant disorders.

- 53 -


27. The composition of any one of claims 22-26 for reducing the metastasis formation in malignant disorders.
28. The composition of claims 26 or 27, wherein the malignant disorder is glioblastomas.
29. The composition of any one of claims 22-26 comprising at least one further active agent.
30. The composition of claim 29, wherein the further active agent is a cytotoxic or cytostatic agent.
31. A method of identifying and/or characterizing an inhibitor of the invasivity of malignant disorders comprising determining, if a test compound is capable of inhibiting the AXL gene, AXL ligand gene, AXL protein and/or AXL protein ligand.
32. The method of claim 31 comprising determining, if a test compound is capable of binding to the AXL protein and/or reducing the AXL gene expression.
33. The method of claim 31 or 32, wherein a cell-based assay system is used.
34. The method of claim 31 or 32, wherein a cell-free assay system is used.

# 3D growth of invasive BC cell lines on Matrigel (6mg/1mg/ml)


MDA-MB-231 (branched, invasive) MBA-MB-435S (branched-stellate, invasive)



BT-549 (stellate, invasive)




MCF10A (duct-like pattern, non invasive), control



all x100

Fig. 1


Fig. 2



Corr: 0.51

TEXT L (b)  
CD44 (b)  
TIMP3 (3a) (b)  
HDC2 (b)  
Caveolin2 (b)  
Caveolin1 (b)  
TIMP2 (2b) (b)  
Ufo/asf L (b)  
MMP14 (12a) (b)  
MDR12 (d)  
M-CSF (b)  
Iva L (b)  
Iva L (b)  
SIRPalpha1 (b)  
Gas6 (b)  
MCH1 (b)  
Statbb (b)  
Statba (b)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100




1.


2.

3.

MDA-MB157E4-KR-  
MDA-MB100R4-KR-  
MDA-MB4355R4-KR-  
MDA-MB415R4-KR-  
MDA-MB231R4-KR-  
MDA-MB436R4-KR-  
H57187E4-KR-  
BT649E4-KR-  
AC-745R4-KR-  
MCF10R4-KR-  
HUVRC  
MDA-MB453R4-KR-  
ZR75-30R4-KR-  
MDA-MB361E4-KR-  
MCF7 (5u) E4-KR-  
BT483E4-KR-  
T47BR4-KR-  
ZR75-1E4-KR-  
DRL4-KR-  
BT474E4-KR-  
SKBR3E4-KR-  
BT20E4-KR-  
MDA-MB468R4-KR-  
MDA-MB175E4-KR-  
DU-44-75E4-KR-  
P1acenta  
BC3640dwt2N1M0II+R4-  
BC181dwt1N1M0II-65R4x  
BC3539dwt2N1M0II+73E4-  
BC3638dwt1N1M0II+R4+  
BC3637lwt2N1M0II+57E4-  
BC3632dwt2N0M0II+44E4+  
BC8335lwt2N2M0II-57E4-  
BC9335lwt2N2M0II-49E4-  
BC6735dwt2N0M0II-37E4+  
BC168dwt2N0M0II+74R4x  
BC177dwt2N1M0II+61R4x  
BC8786dwt1N2M0II+R4+  
BC159dwt1N0M0II-29E4x  
BC5382dwt4N2M0II-56R4+\*  
BC1323dwt2N4M0II-61E4-  
BC1472dwt2N2M0II-R4-  
BC9796dwt2N0M0II+46R4-  
BC13316dwt2N2M0II+71E4-  
BC80dwt2N0M0II-62E4x  
BC8566lwt2N2M0II-68R4-  
BC1015dwt2N4M0II-69E4+  
BC8114dwt4N2M0II+35R4+  
BC14879dwt3N0M0II+46R4-  
BC11218dwt2N3M2IV+59E4-  
BC10555dwt2N0M0II+77\*  
BC12166dwt2N2M0II+45R4+  
BC10681dwt1N0M0II-51E4+  
BC8481dwt2N2M0II-57E4+\*  
BC13932dwt4N2M0II-45R4+  
BC16353dwt4N4M0II-51R4-  
BC11697dwt1N4M0II+67E4+\*  
Blood PIN  
Blood RNC  
BC1844dwt1N0M0II-80R4x  
BC3433dwt2N0M0II+72E4-  
BC151dwt4N1M0II-61E4x  
BC11820dwt4N4M0II-41E4-  
BC10670dwt2N4M0II+82E4-  
P991N0M0II-E4-  
P1356N0M0II-  
P15856N0M0II-  
P19044N0M0II-  
P14860N0M0II-  
P15153N0M0II-E4-  
P15153N0M0II-E4-  
BC1176dwt1N0M0II+76R4x  
BC36310t4N8M0+61E4+  
BC183dwt2N0M0II+41E4x




20 20 20 20 20 20 20 20 20 20



80804dwtZNMOMII+62743K  
 BC9354dwtZNMOMII+4394-  
 BC138232dwtZNMOMII+6144-  
 BC14722dwtZNMOMII-74-  
 BC11820dwtZNMOMII+4144-  
 BC139932dwtZNMOMII+4544+  
 BC5382dwtZNMOMII-5344+\*  
 BC8114dwtZNMOMII+3544+  
 BC6735dwtZNMOMII+3744+  
 BC16353dwtZNMOMII+5144-  
 BC3646dwtZNMOMII+E4-  
 BC11697dwtZNMOMII+6744+\*  
 BC12166dwtZNMOMII+4544+  
 BC1844dwtZNMOMII+80544K  
 BC6331dwtZNMOMII+5144+  
 BC176dwtZNMOMII+7644K  
 BC1828dwtZNMOMII+4144K  
 BC3539dwtZNMOMII+7344-  
 BC3632dwtZNMOMII+4444+  
 BC3638dwtZNMOMII+E4+  
 BC36371dwtZNMOMII+5744-  
 BC177dwtZNMOMII+6144K  
 BC181dwtZNMOMII+65744K  
 BC481dwtZNMOMII+7144-  
 BC3433dwtZNMOMII-7244-  
 BC10150dwtZNMOMII+6944+  
 BC159dwtZNMOMII-2944K  
 BC8786dwtZNMOMII+E4+  
 BC9796dwtZNMOMII+4644-  
 BC13316dwtZNMOMII+7144-  
 BC8481dwtZNMOMII+5744+\*  
 BC168dwtZNMOMII+7444K  
 BC11218dwtZNMOMII+5944-+  
 BC14879dwtZNMOMII+4644-  
 BC8566dwtZNMOMII+6844-  
 BC8335dwtZNMOMII-5744  
 BC10681dwtZNMOMII+5144+  
 BC1904dwtZNMOMII+  
 BC106710dwtZNMOMII+8244-  
 BC10555dwtZNMOMII+77\*  
 MDN-MB43544-KR-  
 HBL100044-KR-  
 BC154dwtZNMOMII-6144K  
 HS57878744-KR-  
 BT54944-KR-  
 MDN-MB45344+KR-  
 MDN-MB15744-KR-  
 DU-44-7544+KR-  
 SKBR344+KR-  
 MDN-MB46844-KR-  
 BT2044-KR-  
 MCE71(Su)44+KR-  
 BT48344+KR-  
 KR75-144+KR+  
 BT4744-KR+  
 MDN-MB36144+KR+  
 KR75-3044-KR+  
 T4744+KR+  
 MDN-MB43644-KR-  
 MC-74544-KR-  
 MCE10344-KR-  
 MDN-MB23144-KR-  
 MDN-MB17544-KR-  
 DML44-KR+

TGT L (b)  
 TGT2 (b)  
 TGT1 (b)  
 Stat6b (b)  
 Stat6a (b)  
 Gas6 (b)  
 Ufo/ard L (b)  
 MMP19, 12a, 12b (b)  
 MMP12 (b)  
 MMP2 (b)  
 Vimentin (b)  
 TIMP3 (3a) (b)  
 JIBKGF (b)  
 KPR2 L (b)  
 MMP17 (b)  
 abl L (b)  
 X-CSF (b)  
 Caveolin2 (b)  
 Caveolin1 (b)  
 CD44 (b)  
 SGK (b)  
 fvn L (b)  
 lvn L (b)  
 SIRPalpha1 (b)  
 SGK1 (b)  
 MMP-1 (b)



## Analysis of expression RTK AXL and GAS by Northern blot




Fig. 4



The 3D outgrowth on Matrigel matrix a different invasive breast cancer cell lines (14 days)

MDA-MB-435S, mock




BT549, mock



MDA-MB-231, mock



-dnAXL, clone 2



-dnAXL, clone 7



-dnAXL, clone 8

**Fig. 5A**

All -dn-AXL clones growth as non invasive, pseudo acinar-fused cancer cells x100





Fig. 5B

## Wound assay


MDA-MB-435S, mock

10%FCS



MDA-MB435S-dnAXL, cl. 2



FCS+GAS6



Starvation 72h



MDA-MB-435S, mock treated by Ex-AXL antibody (ab): 3D growth on MM, 14 days



no ab treatment



+anti-GAS ab




+preimmune serum (R1)

(MDA-MB435S-dnAXL cl2, 14 days on MM)



treatment by -Ex-AXL ab: fused outgrowth



(pseudo acinar or fused)

×100 all

Fig. 6A

# The invasiveness of MDA-MB-435S cells treated by Ex-AXL antibody




Fig. 6B





Fig. 6C


The morphology of breast cancer cell line MCF7  
with forced over-expression RTK AXL wt

mock


AXL wt



x100



x320



x320





Fig.7A





**Fig. 7B**

Figure 8




Figure 9






Figure 10





Figure 11



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number  
WO 2004/008147 A3

(51) International Patent Classification<sup>7</sup>: G01N 33/574,  
A61P 35/04, 35/00

(21) International Application Number:  
PCT/EP2003/007786

(22) International Filing Date: 17 July 2003 (17.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02015944.8 17 July 2002 (17.07.2002) EP

(71) Applicant (for all designated States except US): MAX-  
PLANCK-GESELLSCHAFT ZUR FÖRDERUNG  
DER WISSENSCHAFTEN E.V. [DE/DE]; Hofgartenstr.  
8, 80539 Munich (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ULLRICH, Axel  
[DE/DE]; Brunnstr. 5, 80331 Munich (DE). KNYAZEVA,  
Pjotr [RU/DE]; Hubertusstr. 66, 82131 Gauting (DE).  
KNYAZEVA, Tatjana [RU/DE]; Hubertusstr. 66, 82131  
Gauting (DE). CHEBURKIN, Yuri [RU/DE]; Agnesstr.  
10, 80798 Munich (DE).

(74) Agents: WEICKMANN, Franz, Albert et al.; Weick-  
mann & Weickmann, Postfach 860 820, 81635 München  
(DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

[Continued on next page]


(54) Title: DIAGNOSIS AND PREVENTION OF CANCER CELL INVASION

### 3D growth of invasive BC cell lines on Matrigel (6mg/1mg/ml)

MDA-MB-231 (branched, invasive) MBA-MB-435S (branched-stellate, invasive)



BT-549 (stellate, invasive)



MCF10A (duct-like pattern, non invasive),  
control



all x100

(57) Abstract: The present invention relates to diagnostic and therapeutic methods in the field of malignant disorders. More particularly, the invention provides methods of determining the invasivity of malignant disorders and methods for reducing the invasivity of malignant disorders including the prevention or treatment of cancer cell invasion.

WO 2004/008147 A3



**(88) Date of publication of the international search report:**  
27 May 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/EP/07786

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/574 A61P35/04 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, MEDLINE, EMBASE, CHEM ABS Data, EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DOMAGALA W ET AL: "VIMENTIN IS PREFERENTIALLY EXPRESSED IN HUMAN BREAST CARCINOMAS WITH LOW ESTROGEN RECEPTOR AND HIGH KI-67 GROWTH FRACTION" AMERICAN JOURNAL OF PATHOLOGY, vol. 136, no. 1, 1990, pages 219-228, XP008006515 ISSN: 0002-9440 cited in the application abstract  --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 January 2004

Date of mailing of the international search report

22. 01 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gundlach, B

# INTERNATIONAL SEARCH REPORT

Patent Application No  
PCT/EP 03/07786

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BACHMEIER BEATRICE E ET AL: "Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity." ANTICANCER RESEARCH, vol. 21, no. 6A, November 2001 (2001-11), pages 3821-3828, XP008006514 ISSN: 0250-7005 cited in the application abstract	1
A	WO 92 17608 A (BIRCHMEIER WALTER) 15 October 1992 (1992-10-15) abstract claim 1 example 4	1
X	ATTAR, E. C. ET AL: "Axl receptor tyrosine kinase expression in human breast cancer." BREAST CANCER RESEARCH AND TREATMENT, (OCT., 1997) VOL. 46, NO. 1, PP. 91 MEETING INFO.: 20TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM SAN ANTONIO, TEXAS, USA DECEMBER 3-6, 1997, October 1997 (1997-10), XP008006520 abstract	1-9
X	DODGE ZANTEK N. ET AL: "MCF-10A-NeoST: A new cell system for studying cell-ECM and cell-cell interactions in breast cancer." CLINICAL CANCER RESEARCH, 7/11 (3640-3648)., November 2001 (2001-11), XP001074226 page 3646, right-hand column, paragraph 5 -page 3647, left-hand column	1-9
A	FRIDELL YIH-WOEI C ET AL: "GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 12, 20 March 1998 (1998-03-20), pages 7123-7126, XP002154999 ISSN: 0021-9258 abstract	1-9

-/-

# INTERNATIONAL SEARCH REPORT

Application No  
PCT/EP 03/07786

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WU CHEW-WUN ET AL: "Clinical significance of AXL kinase family in gastric cancer." ANTICANCER RESEARCH, (2002 MAR-APR) 22 (2B) 1071-8., XP008006835 abstract page 1075, left-hand column, paragraph 2 -page 1076, left-hand column, paragraph 2	1-9
X	MERIC F. ET AL: "Expression profile of tyrosine kinases in breast cancer." CLINICAL CANCER RESEARCH, 8/2 (361-367).., February 2002 (2002-02), XP001074227 abstract page 366, left-hand column, paragraph 2	1-9
X	BERCLAZ G ET AL: "Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast." ANNALS OF ONCOLOGY, (2001 JUN) 12 (6) 819-24., XP008006834 abstract page 821, left-hand column, paragraph 2 -page 822, right-hand column, paragraph 1	1-9
X	WO 00 76309 A (VLAAMS INTERUNIVERSITAIR INST ;COLLEN DESIRE (BE); CARMELIET PETER) 21 December 2000 (2000-12-21) page 6; claims 4-10	10-34
X	KRUPITZA G ET AL: "GENES RELATED TO GROWTH AND INVASIVENESS ARE REPRESSED BY SODIUM BUTYRATE IN OVARIAN CARCINOMA CELLS" BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 73, no. 4, 1 February 1996 (1996-02-01), pages 433-438, XP000574908 ISSN: 0007-0920 abstract page 435, left-hand column, paragraph 6 -right-hand column, paragraph 1; figure 3	10,11, 15-18, 22, 26-28,31
P,X	ITO M ET AL: "Expression of receptor-type tyrosine kinase, Axl, and its ligand, gas6, in pediatric thyroid carcinomas around chernobyl" THYROID 01 NOV 2002 UNITED STATES, vol. 12, no. 11, 1 November 2002 (2002-11-01), pages 971-975, XP008026096 ISSN: 1050-7256 abstract	1-11

-/--

## INTERNATIONAL SEARCH REPORT

Application No  
PCT/EP 03/07786

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	SASAKI TAKAKO ET AL: "Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 46, 15 November 2002 (2002-11-15), pages 44164-44170, XP001168602 ISSN: 0021-9258 abstract	10, 11, 14
A	WO 01 78778 A (VLAAMS INTERUNIVERSITAIR INST ; CARMELIET PETER (BE); LEUVEN RES &) 25 October 2001 (2001-10-25) the whole document	1-34
A	PEDROCCHI M ET AL: "EXPRESSION OF CA2+-BINDING PROTEINS OF THE S100 FAMILY IN MALIGNANT HUMAN BREAST-CANCER CELL LINES AND BIOPSY SAMPLES" INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 57, no. 5, 1 June 1994 (1994-06-01), pages 684-690, XP001064860 ISSN: 0020-7136 the whole document	1-34



INTERNATIONAL SEARCH REPORT

national application No.  
PCT/EP 03/07786

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 18, 20, 22-25 (all partially)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
All claims were searched concerning AXL and GAS-6
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☒ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.1

Although claims 10-21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

## Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

-----

## Continuation of Box I.2

Claims Nos.: 18, 20, 22-25 (all partially)

Present claims 22, 24, 26-30 relate to compounds defined by reference to a desirable characteristic or property, namely being active inhibitors of AXL gene/protein.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the examples (pages 16-23).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: Claims 1,2,4-9 (partially), 3,  
10-34 (fully)

Determination/treatment of invasivity of cancer cells using  
AXL as presented in claim 1

Inventions 2-17: Claims 1,2,4-9 (partially)

Determination/treatment of invasivity of cancer cells using  
one of the further markers (not AXL/GAS-6) as presented in  
claim 1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/07786

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9217608	A	15-10-1992	DE 4110405 A1 01-10-1992
		AT 158344 T 15-10-1997	
		DE 59208916 D1 23-10-1997	
		WO 9217608 A1 15-10-1992	
		EP 0582582 A1 16-02-1994	
		JP 7500723 T 26-01-1995	
WO 0076309	A	21-12-2000	AU 5077100 A 02-01-2001
		WO 0076309 A2 21-12-2000	
		EP 1185635 A2 13-03-2002	
WO 0178778	A	25-10-2001	EP 1199081 A1 24-04-2002
		AU 6021401 A 30-10-2001	
		WO 0178778 A1 25-10-2001	
		EP 1272217 A1 08-01-2003	
		US 2003144237 A1 31-07-2003	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**